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ABSTRACT OF THE DISSERTATION 
 
The Impact of Interferon Regulatory Factor 3 on the Immune Response to Herpes 
Simplex Virus Type 1 Infection 
By 
Vineet David Menachery 
Doctor of Philosophy in Biology and Biomedical Sciences   
(Immunology) 
Washington University in St. Louis, 2010 
Dr. David A. Leib & Dr. Michael S. Diamond, Co-Chairs 
The type I interferon (IFN) cascade is critical in control of herpes simplex virus 
type I (HSV-1) infection and  relies on specific recognition molecules to rapidly signal 
viral infection via interferon regulatory factor-3 (IRF-3) -dependent pathways.  The 
absence of these recognition molecules or the loss of IRF-3 would be predicted to render 
early recognition pathways inoperative and thus impact viral infection.  However, 
previous results had produced contradictory results in terms of the role of IRF-3 during 
HSV-1 infection. In this study, infected IRF-3-/- immune cells were found to support 
increased HSV-1 replication compared to control cells.  In addition, IRF-3 deficient cells 
exhibited delayed type I IFN synthesis following infection and were partially restored in 
the presence of exogenous IFN;  blockade of the type I IFN receptor resulted in similar 
titers in control and IRF-3-/- cells. Together, the data demonstrated that defective and 
deficient type I IFN production in IRF-3-/- cells resulted in increased HSV-1 replication in 
vitro.  In vivo, IRF-3 deficiency was found to have no significant impact on HSV-1 
replication in peripheral tissues following ocular challenge with a laboratory (17) or a 
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neurovirulent strain (McKrae) of virus.  However,  IRF-3-/- mice were significantly more 
susceptible to central nervous system infection following both peripheral and intracranial 
infection with HSV-1.  Increased viral replication and inflammatory cytokine production 
were observed in brain tissues of IRF-3-/- mice compared to control mice.  In addition, the 
production of IFNβ and IFNα was delayed and reduced in IRF-3-/- brains.  These data 
demonstrate a critical role for IRF-3 in control of central nervous system infection 
following HSV-1 challenge.  Together, the data illustrate the importance of IRF-3 
mediated pathways in initiating the type I IFN cascade necessary to control HSV-1 
infection both in vitro and in vivo.   
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Chapter I 
 
Introduction  
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The Herpes Virus Family 
Herpesviridae constitutes a family of ubiquitous viruses that infect a variety of 
hosts ranging from fish to mammals (122). The nearly 130 identified members of the 
herpesvirus family are divided into three subfamilies on the basis of biological properties: 
Alpha-, Beta-, and Gamma- herpesviruses (165).  Alphaherpesviruses, which include 
herpes simplex virus type 1 (HSV-1) and herpes simplex type 2 (HSV-2), have a variable 
host range, short reproductive cycle, rapid spread, and lyse host cells in vitro and in vivo.  
In contrast,  betaherpesviruses, which include human cytomegalovirus (HCMV) and 
murine cytomegalovirus (MCMV) ,  have a restricted host range, a long life cycle, and 
grow slowly in culture.  Finally, gammaherpesviruses are restricted to the family or order 
of their natural host and include Epstein Barr Virus (EBV);  the members of this group 
effectively replicate within immune cells especially T and B lymphocytes (165).  Despite 
initial classification based mainly on biological properties, nucleic acid and protein 
sequence similarities have since validated grouping into these functional families.  
However, each member of the herpesviridae family shares several significant properties. 
The hallmark of the herpes virus family is the ability to establish latency and a 
lifelong infection.  Latency is characterized by limited viral gene expression, stable 
maintenance of the viral genome, and the absence of infectious virions (165).   While the 
stimuli remain unknown, herpesviruses in the latent state are periodically induced to 
reactivate causing recurrent infection in the host.  The absence and reemergence of 
infectious virus distinguish latency from chronic or abortive infections respectively.  
Establishment of latency in varying cell types also distinguishes between the three 
herpesvirus families.  Alphaherpesviruses establish latency within sensory ganglia; 
3 
 
betaherpesviruses establish latent infection in secretory glands, lymphoreticular cells, the 
kidney, and other tissues.  Finally, gammaherpeseviruses frequently establish latency in 
lymphoid tissues, specifically B and T-cells.  
Despite the wide host ranges, each member of the herpesvirus family also 
maintains a similar structure with four distinct components:  core, capsid, tegument, and 
envelope (165).   The inner core contains the linear double-stranded DNA genome which 
is surrounded by an icosohedral capsid made up of viral proteins.  The lipid envelope 
makes up the outer most layer of the virion and is composed primarily of host cellular 
membrane and viral glycoproteins.  These viral glycoproteins are non-randomly 
distributed throughout the envelope and form the spikes associated with herpes virions.  
Finally, the tegument separates the envelope from the capsid; the amorphous tegument is 
made up of several viral proteins that function in the host cytoplasm, nucleus, or both.  
Many of these proteins are dispensable for viral replication, but appear critical for 
virulence.   Together, these components form herpes virions ranging in size from 120 to 
nearly 300nm with tegument thickness and envelope composition contributing to the 
variability in size.   
In addition to similar structure, the herpesvirus family shares several common 
traits during infection.  Each utilizes glycoproteins within the envelope to mediate 
binding, attachment, and fusion to the host cell.  Upon entry, herpesviruses traffic their 
genome and other components to the nucleus where viral transcription, DNA replication, 
capsid formation, and packaging of viral DNA occur. Utilizing its large double-stranded 
DNA genome, herpesviruses also encode a wide array of proteins involved in nucleic 
acid metabolism, DNA synthesis, protein processing, and immune antagonism.  
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Following DNA packaging, capsids acquire and lose a primary envelope composed of the 
nuclear membrane.  Finally, the tegument and envelope are acquired in the cytoplasm and 
the progeny virions are prepared to exit the cell.  Production of infectious herpesvirus 
progeny, in contrast to latency, results in destruction of the infected host cell. 
 
Herpes Simplex Virus Type I 
 The thesis work described herein focuses on infection with herpes simplex virus 
type I (HSV-1), a member of the alphaherpesviridae family (165).  HSV-1 is a 
widespread human pathogen that has high seroprevalence in adults (222).  Among the 
first human herpes viruses to be discovered, HSV-1 infection has served as a research 
model in numerous areas including the nervous system, membrane structure, and gene 
regulation, in addition to infectious disease (164).  HSV-1 infection also causes numerous 
diseases in humans and is the target of on-going vaccine research (96).   
 
Structure 
 Like all herpesviruses, HSV-1 is composed of the four major structural 
components: genomic core, capsid, tegument, and envelope. The virus has a large double-
stranded DNA genome comprised of nearly 150 kilo-base pair divided into a unique long 
and unique short region  (121, 163).  Enclosed within the viral capsid, the genome 
encodes as many as 84 unique genes involved in the viral life cycle (164).  In addition to 
the capsid, the viral envelope, composed of viral glycoproteins and host cell membrane, 
encases the HSV-1 tegument.  The tegument, which constitutes the layer between the 
envelope and capsid, is released into the cytoplasm shortly after infection  (132).  The 
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tegument is among the best-characterized and most studied groups of viral proteins and is 
critically involved in HSV-1 life cycle.   
 
Viral Replication 
HSV-1 replication is divided into several major events.  Infection is initiated via 
attachment of viral glycoprotein C and B (gC and gB) to the cell surface, glycoprotein D 
binding of cell-surface co-receptors, and fusion of the viral envelope and plasma 
membrane(154, 164, 188-189, 208). Following fusion, the capsid is transported to the 
nucleus and the tegument proteins are released into the cytoplasm, accompany the DNA 
into the nucleus, or remain associated with the capsid (164, 205).  In the nucleus, viral 
transactivators, in combination with the host machinery, initiate ordered transcription of 
viral genes divided into four kinetic classes (213).  The α genes, the immediate early 
kinetic class, consist of five viral proteins that prime the transition from cellular to viral 
gene expression (164).  The β genes, the early kinetic class, follow the α genes with 
expression of viral proteins involved in replication of viral DNA.  The γ1 genes, the leaky 
late genes, can actually be expressed prior to DNA replication, but their maximal 
expression is DNA replication-dependent. These γ1 genes include structural proteins, 
glycoproteins, and immune antagonists.   Finally, the γ2 genes, the true late structural 
genes, are expressed and are dependent on viral DNA synthesis for expression.   
Following γ1 gene expression, synthesis of progeny virions is initiated.  The 
capsid protein, a γ1 gene, localizes to the nucleus for insertion of the viral DNA (131, 
164).  The complete nucleocapsid then egresses through the nuclear membrane and 
eventually into the golgi apparatus acquiring tegument proteins during the process.  
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Within the golgi apparatus, final maturation of the viral glycoprotein occurs and the 
virion is ready to infect a new cell either through release through the plasma membrane 
or through direct cell-to-cell contact (164, 207). Productive HSV-1 infection results in 
death of the host cell due to a variety of cellular responses to infection including changes 
in host chromatin, alteration of cell membranes, and formation of intranuclear inclusion 
bodies (164).   
 
Life cycle and Latency 
  As mentioned earlier, the ability to establish a lifelong latent infection is the 
hallmark of herpesvirus infections (165).  During HSV-1 infection, the virus life cycle 
begins with lytic replication in peripheral mucosal epithelia  (164).  The virus is then able 
to enter the nerve termini and is transported through the axon in a retrograde fashion to 
the sensory ganglia (105).  Upon reaching the ganglia, the virus can continue a lytic 
infection in neurons. Following entry into the CNS during acute primary infection HSV 
can cause life-threatening encephalitis; however, the virus usually shifts to a quiescent 
latent state in the peripheral nervous system,, in sensory ganglia.  The latent state is 
characterized by an episomal viral genome, the production of latency-associated 
transcripts (LATs), and the lack of infectious progeny virions (165).  The host immune 
system also contributes to the establishment of latency by suppressing infection and 
limiting spread (13, 204).  Inflammation and CD8+ T-cells have also been implicated in 
maintaining HSV-1 in a latent state (37-38).  Periodically, the latent HSV-1 is induced to 
reactivate via “stress” stimuli including immune suppression, physical/emotional stress, 
or exposure to ultraviolet (UV) light (164).   Reactivated viral particles are then 
7 
 
transported in an anterograde direction from the sensory neuron to the primary site of 
infection resulting in asymptomatic shedding or recurrent infectious lesions at the 
original infection site (105).    
 
Clinical manifestation 
 HSV-1 infection is wide spread in the human population reaching 70-80% 
prevalence in  the adult population (222).  The host first encounters the virus via contact 
with secretions, skin, or mucosal membranes from symptomatic or asymptomatic 
individuals shedding virus (218).  Oral infection often results in the most frequent 
manifestation of HSV-1 infection: herpes simplex labialis, the common cold sore (46).  
Following primary oral infection, HSV-1 establishes latency in the trigeminal ganglia;  
periodic “stress” stimuli result in reactivation and result in HSV-1 induced cold sores at 
the initial site of infection in 20-40% of HSV-1 seropositive individuals (8).  In immune 
competent individuals, recurrent infection is less severe than primary infection and is 
controlled within 1-10 days after initial onset of symptoms (152).  HSV-1 is also 
associated with genital herpes, herpetic stomatitis in the mouth, and cutaneous herpetic 
infections like herpetic whitlow, eczema herpeticum, and herpes gladiatorum(8) .  In 
general, these infections are resolved in immune competent host and cause minimal long 
term damage.  
In contrast, HSV-1 infection may lead to serious infection of the eye and the CNS. 
Infection of ocular tissue resulting in serious eye disease can happen via direct entry or 
spread from non-ocular sites like the mouth (90).  Ocular HSV-1 infection often initiates 
severe immune reactions inducing blepharitis, conjunctivitis, retinitis, iridocyclitis, 
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epithelial and stromal keratitis (8, 206).  Herpetic stromal keratitis (HSK), a condition 
that results in stromal damage, scarring, and loss of vision, is among the leading causes of 
infectious blindness in developed countries (152).  In addition to ocular disease, HSV-1 
remains among the most common causes of viral encephalitis (92-93).  Herpes simplex 
encephalitis (HSE) is a rare, but life threatening consequence of infection of the nervous 
system (209).  Through recurrent infection in adults or maternal transmission to neonates, 
HSV-1 infects the brain and causes acute inflammation and significant pathological 
damage (92-93, 217).  If untreated, HSE mediated damage leads to nearly 70% lethality 
and few patients return to normal function (209).   
 
Diagnosis, treatments, and vaccines 
 Diagnosis of HSV-1 infection is typically based on clinical histology and 
presenting features, although various tests have been developed to confirm HSV-1 
infection including changes in cytology, plaque assay, and serological methods (8).  
However, detection of viral DNA by PCR is generally considered to be the most sensitive 
measure for presence of HSV-1 (22).  Therapy for HSV-1 infection ranges from no 
treatment to a combination of antiviral drugs and corticosteroids (78, 179).  The most 
commonly utilized drug against HSV-1 is acyclovir, a nucleoside analogue (8).  
Acyclovir is converted to its active form by viral thymidine kinase and incorporated into 
viral DNA acting as a chain terminator and inhibiting viral replication (220). Acyclovir 
also targets the viral DNA polymerase (ref).  It can be given topically, orally, and 
intravenously permitting it to treat a variety of HSV-1 infections including ocular, 
genital, or HSE (8).  Additional treatment utilizing corticosteroids to dampen the immune 
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response to viral infection have also been explored, but the results remain unclear on its 
efficacy or side-effects (78).   
Research continues to develop new treatments for current HSV-1 infections and 
preventative measures to impede future infection.  While the majority of HSV-1 drugs are 
nucleotide analogues that interfere with viral replication, several new categories of 
antiviral drugs are being examined including helicase inhibitors, TLR agonist, and 
therapeutic vaccines (220).  In addition, work continues on development of a vaccine that 
confers protection against HSV-1 infection.  Both subunit based and live-attenuated 
HSV-1 vaccines have been examined for efficacy in animal models and clinical trials 
(96-97).  Yet, none to date have been effective in protection (95, 220).  Several factors 
contribute to the difficulty in developing a HSV-1 vaccine, most notably opposition to the 
use of a live-attenuated vaccine, and a failure of subunit vaccines to establish robust local 
mucosal immunity (220).  
 
Animal models 
 For HSV-1 research, a variety of animal models have been studied that mimic 
human disease including rabbits and guinea pigs (72, 107, 151, 203, 218).  However, the 
mouse model of HSV-1 infection remains among the most common and practiced 
methods for in vivo research (151).  The outcome of HSV-1 infection in mice is highly 
dependent on a variety of factors including virus and mouse strain, competence of the 
immune system, and route of infection.  For example, certain virus strains such as HSV-1 
strain McKrae are more virulent in mice than other HSV-1 strains, though the exact 
mechanism for the change in virulence is unclear (153).  In addition, mouse strains like 
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C57BL/6 are more resistant to HSV-1 challenge than Balb/C mice; these difference in 
strains have been attributed to changes in the innate immune response (115).  Mice 
deficient in immune pathways have also been demonstrated to have increased 
susceptibility or alternatively, enhanced resistance to viral infection (108, 116, 144).  In 
addition, the route of infection plays a major role in determining the pathogenesis of 
HSV-1 in vivo.   Together, these factors permit evaluation of several elements of HSV-1 
infection.  In these studies, two routes of in vivo HSV-1 infection are utilized:  ocular 
infection via corneal scarification and direct intracranial inoculation.   
 The ocular route of infection provides a physiologically relevant model for HSV-
1 infection in vivo (107).  To mimic human disease,  mouse eyes are scarified to permit 
viral infection of the corneal stroma; stromal infection results in lytic infection at the 
primary site of infection and HSV-1 can then enter the nerve termini that innervate that 
region of the cornea (105). The virus is then transported in a retrograde manner, through 
the axon to the trigeminal ganglia; HSV-1 replication in the trigeminal ganglia can be 
measured as early as day 1 and peaks between day 3-6 post infection (218).   HSV-1 can 
continue to travel to the brain in a retrograde spread, or travel in an anterograde direction 
leading to infection of the periocular skin, a measure of zosterform spread from the 
trigeminal ganglia back to new peripheral tissues (14, 193).   Viral titers in the cornea are 
measured via eye swab while the trigeminal ganglia, brain, and periocular skin can all be 
measured via plaque assay of harvested tissue homogenates.    
In addition to examination of primary disease, the cornea model of infection also 
permits evaluation of latency (218).   The two primary measures of latency are 
establishment and reactivation.  Establishment refers to the presence of the HSV-1 
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genome in the trigeminal ganglia in the absence of viral replication; by 28 days post 
ocular infection, HSV-1 replication is no longer detectable and establishment is evaluated 
by PCR for viral DNA (23, 201).  Reactivation refers to the ability of the virus to shift 
from latency to lytic infection and is typically measured by peripheral shedding of virus.  
In vivo, mice have a very low rate of spontaneous reactivation compared to humans or 
rabbits (141, 218); however, exposure to UV light in vivo or ex-vivo transplantation of 
trigeminal ganglia permits measurement of viral reactivation (107, 184).  In recent years, 
examination of in situ hybridization in the trigeminal ganglia of latently infected mice has 
revealed “rare neurons” that express high levels of lytic HSV-1 transcripts, viral DNA, 
and protein (47).  This low level of lytic antigen production absent infectious virus has 
been termed molecular reactivation and likely contributes to the generation of immunity 
during latency (47, 52, 94).   
Both the ocular and the intracranial injection models evaluate the ability of  HSV-
1 to invade and replicate within the CNS (42).  Cornea infection results in trafficking of 
the virus from the periphery into the brain and permits examination of neuroinvasiveness 
(105).  HSV-1 replication in the brain also provides a measure of viral fitness in the CNS; 
however, several factors impact neuroinvasiveness including replication kinetics in 
peripheral tissues, ability to be efficiently retrogradely transported,  and actions of the 
immune system.  Neuroinvasiveness is highly virus and mouse strain dependent(12, 42, 
117). To control for these external factors in peripheral tissues, HSV-1 infection via 
direct intracranial inoculation permits evaluation of the virus’ ability to replicate within 
the brain tissues (42).  This CNS model of infection mimics human HSE and results in 
high morbidity and mortality rates in vivo.  Together, the ocular and intracranial 
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inoculation routes provide in vivo mouse models for two important HSV-1 human 
diseases. 
 
The Immune Response to Virus 
In response to viral infection, interferons induce signaling cascades that arm 
immune defenses and provide the initial line of defense against invading pathogens and 
malignant cells (77).  The term interferon was originally derived from the ability of these 
secreted factor to “interfere” with viral replication in host cells (77, 169).  Divided into 
type I and II categories, interferons initiate transcription of hundreds of genes through 
binding their individual receptors (84, 155).  The products of these interferon stimulated 
genes have anti-viral, immune-modulatory, and cell regulatory functions which are 
critical in the control of viral infection in vitro and in vivo(56, 84, 169).  In the absence of 
either the type I or type II interferon cascades, the host fails to mount effective immune 
responses and becomes very susceptible to pathogen and tumor challenge (21, 73, 108, 
129, 210).  Therefore, interferons play a critical role in initiating the immune response to 
viral challenge. 
Type I interferon, also known as viral IFN, can be produced by nearly every cell 
type within the host (169).  Located together on chromosome 9 in humans or 
chromosome 4 in mice, type I IFN genes are divided into several categories including  
IFNβ, IFNα, IFN-w and IFN-t (155, 177).  While the need for multiple types remains 
unclear, each form of type I IFN shares structural homology that permits binding to the 
single, common type I IFN receptor (155).   The type I IFN receptor is composed of two 
subunits, IFNAR1 & 2, which are associated with Janus activated kinase (JAK) 1  and 
tyrosine kinase (TYK) 2 (34, 155).   Upon binding of type I IFN, the IFNAR stimulates 
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auto-activation of JAK1 and TYK2 resulting in tyrosine phosphorylation of STAT1 and 
STAT2.  The phosphorylated STAT1 and STAT2 form heterodimers and in conjunction 
with interferon regulatory factor nine (IRF9), become the IFN-stimulated gene factor 3 
(ISGF- 3)(34, 155).  This complex travels to the nucleus and binds IFN-stimulated 
response elements (IRSE) in the DNA and initiate the type I IFN cascade.  
In contrast to type I, type II IFN consists of a single form, IFNγ.  Structurally 
distinct from the type I IFNs, IFNγ is produced mainly by T-cells and natural killer cells 
and targets immune cells including macrophages (77, 155, 169, 177).  Upon binding 
IFNγ, the two subunits of the type II receptors, IFNG1 and IFNG2, induce the 
phosphorylation of STAT1 via JAK 1 and JAK 2 (155).  The phosphorylated STAT1 
forms a homodimer and translocates to the nucleus, binding to IFNγ activated sites 
(GAS) elements upstream of target ISGs.  This leads to the transcription of numerous 
target genes and various outcomes that encompass the type II IFN cascade (77, 84, 169).   
While both type I and type II IFN have been shown to be necessary in the control 
of viral replication in vitro and in vivo (21, 73, 108, 129, 210),  the recognition pathways 
of the immune system, the focus of this thesis,  primarily produce type I IFN in response 
to viral challenge.  Therefore, herein, the focus will be on the type I IFN system with 
implicit acknowledgement of the importance of type II IFN in control of viral infection. 
 
Interferon Stimulated Genes and Down Stream Effects. 
While type I interferon has no reported enzymatic activity, the hundreds of 
induced interferon stimulated genes (ISGs) mediate a variety of biological responses that 
impact the ability of the virus to function and can elicit an anti-viral state within the cell 
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(84, 155).  Among the most prominent anti-viral ISGs is the dsRNA-activated 
serine/threonine protein kinase, PKR.  Upon binding double-stranded RNA, PKR is 
activated and phosphorylates eIF2 leading to inhibition of protein translation (51, 169).  
Several antiviral ISGs target other parts of the virus replication cycle, for example, 2’5’ 
oligoadenylate synthetase and RNase L  target viral RNAs for degradation (84, 162).  The 
myxovirus-resistance proteins (Mx), IFN-inducible GTPases, were among the first 
studied ISGs and have broad functions in both the nucleus and cytoplasm on multiple 
types of viruses (77, 166, 169).   ISG15, originally identified as a ubiquitin homologue, 
protects against viral mediated degradation of immune components or modifies 
enzymatic function to enhance the antiviral state (166).   Yet, only a minor population of 
ISGs have been fully evaluated in vitro or in vivo. 
Type I IFN signaling is thought to induce or modify nearly 2000 genes.  While 
well over 300 have been identified to be highly induced via microarray studies, the 
majority of these ISGs have been categorized as having no “direct”  antiviral activity; 
instead, they encompass a wide variety of functions that contribute to the antiviral state 
(36).  Type I IFN signaling has been shown to have immuno-modulatory and cell 
regulatory functions (84, 169).  Studies have demonstrated an increase in expression of 
MHC class I and II, necessary components for antigen presentation to T-cells (36, 77, 
166).  Similarly, several ISGs encode chemokines and adhesion molecules critical for the 
trafficking of lymphocytes to the area of infection (36).   IFN signaling also leads to 
increased expression of signaling molecules and transcription factors often involved in 
the inflammatory response (36, 155).  IFN has been shown to upregulate genes involved 
in both protein degradation as well as apoptosis (10, 36).  Numerous other ISGs have yet 
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to even be categorized and fully evaluated.  Together, in combination with the known 
antiviral ISGs, IFN mediated effects result in host cells being rendered inhospitable to 
virus infection. 
 
IFN, ISG, and HSV-1 antagonism 
Naturally, viruses have developed mechanisms to interfere with type I IFN and its 
downstream effects (55, 84, 177).  At any step within the type I IFN cascade, viruses can 
block, sequester, or inhibit elements of the IFN signaling machinery.  In addition, 
successful viruses often antagonize the production or function of ISGs, most notably 
PKR and RNaseL (84).  HSV-1 is among the most adept viruses at subverting the 
immune response; it encodes several viral proteins that delay and interfere with the type I 
IFN cascade through known, and yet to be determined, mechanisms.   
Among the best characterized mechanisms of viral antagonism of immunity is 
HSV-1 neutralization of the PKR pathway.  HSV-1 encodes a protein, ICP34.5,which has 
been implicated in a variety of functions including inhibiting autophagy, processing 
glycoproteins, and facilitating nuclear and cytoplasmic egress (16, 79, 146).  Its most 
prominent function, however, has been associated with interfering with host-protein 
shutoff .  ICP34.5 recruits protein phophatase 1a (PP1) and directs it to dephosphorylate 
eIF-2, the target of activated PKR (60-61). The reduction in phosphorylated eIF-2 
removes the PKR induced block and permits viral protein synthesis to continue 
uninterrupted.  In the absence of ICP34.5,  HSV-1 is highly neuroattenuated in vivo with 
restoration occurring only in PKR-/- mice (110).  In addition to ICP34.5, HSV-1 encodes 
a second PKR antagonist, US11.  US11 acts by binding directly to PKR and preventing 
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activation by dsRNA or PACT (40).  A suppressor mutant lacking ICP34.5 had partial 
restoration if US11 was under control of an immediate early promoter (25-26, 215).  
Together, these data demonstrate that multiple HSV-1 proteins target PKR and 
downstream pathways that contribute to the anti-viral state. 
In addition to ICP34.5 and US11, the virus encodes several other known immune 
antagonists.  ICP0, an immediate early transactivator of HSV-1, interferes with several 
aspects of the type I IFN cascade including STAT-1 signaling, with induction and 
function of ISGs, and resistance to type I IFN signaling (43, 59, 135, 137-138, 187).  The 
virion host-shut off protein (vhs), a viral riboendonuclease,  has also been implicated in 
antagonizing the ISG antiviral response by degrading host transcripts, targeting type I 
IFN receptors, and interfering with the activity of JAK/STAT pathway through activation 
of the suppressor of cytokine signaling 3 (SOCS-3) (29, 226-227).   In the absence of 
either ICP0 or vhs, HSV-1 becomes very sensitive to type I IFN and the virus is 
attenuated both in vitro and in vivo (113, 137).   However, mutants lacking ICP0 or vhs 
are partially restored in hosts lacking type I IFN signaling implying their action the type I 
IFN cascade (108, 148, 150).  In more recent work, ICP27, an immediate early viral 
protein,  has been identified in interfering with JAK/STAT signaling and the activity of 
ISG15 (80-81).   
These five viral proteins (ICP34.5, US11, ICP0, vhs, and ICP27) represent the 
best characterized immune antagonists encoded by HSV-1.  Yet, other viral proteins have 
also been implicated in influencing the antiviral state including ICP47 and UL13 (19, 
145, 183, 227).  In addition, the virus has been found to counter several antiviral 
processes including RNaseL and 2’5’ oligoadenylate activity,  although no conclusive 
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mechanism has been established.  Together, the data demonstrate that HSV-1 employs 
significant genetic capital in neutralizing type I IFN and its downstream cascade.    
 
Pathogen Recognition Pathways 
While type I IFN and its downstream effects have been examined for several 
decades, recent research has focused on the pathways that induce the type I IFN cascade 
(18, 67, 178).  Over the past few years, the discovery of pattern-recognition receptors 
(PRRs), adaptors, and signaling molecules has provided detailed mechanisms for the 
recognition of a variety of invading pathogens.  The host immune system relies on these 
early recognition pathways to identify infection and induce the production of type I IFN, 
specifically IFN.  In the past few years, the area of pattern recognition has been divided 
into two branches: the extracellular recognition pathway comprised of the toll-like 
receptor family (TLR)  and the intracellular recognition pathway represented by the Rig-I 
like receptors (RLR) (18).   Each family provides surveillance for specific areas within 
the host cell environment and utilizes adaptors and signaling molecules to drive 
production of IFN following infection. 
 
Toll-Like Receptor Signaling 
 The toll-like receptor (TLR) family consists of several transmembrane receptors 
that recognize pathogen-associated molecular patterns (PAMPs) (3).  TLRs sample 
extracellular contents surrounding host cells either through expression on the cell surface 
or within endosomes.  Originally discovered in Drosophila, 10 TLR genes are expressed 
in mice and humans; each recognizes distinct PAMPs associated with bacteria, viruses, or 
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fungi (3, 77, 86, 111).  Together, these receptors play a key role in activating immune 
cells inducing phagocytosis, cytokine secretion, and enhanced antigen presentation in 
response to infection (77).    
 The majority of the TLRs most commonly associated with viral recognition bind 
nucleic acid motifs within the endosome.  TLR3 was among the first to be characterized 
binding poly IC and double-stranded RNA (4).  In a similar fashion, TLR9 was found to 
recognize unmethylated DNA and both TLR7 and 8 bind to single-stranded RNA 
elements (62-63).  In addition to recognition via nucleic acid motifs, viruses have also 
been described to activate TLR2 and TLR4 through recognition of viral proteins (65, 104, 
235).  Together, the data demonstrate that multiple TLR pathways are involved in the 
recognition of viral pathogens. 
With the exception of TLR3, each of the TLRs transmits its downstream signals 
via myeloid differentiation primary response gene 88 (MYD88) (199).  This adaptor is 
recruited via its C-terminal Toll-IL-1 receptor (TIR) domain which interact with the TIR 
domains found within the TLRs(20, 123).   Upon stimulation, MYD88 recruits IL-1R 
associated kinase (IRAK) via its N-terminal death domain (216); IRAK is then activated 
by phosphorylation and in association with  tumor necrosis factor receptor-associated 
factor 6 (TRAF6), which leads to activation of JNK and NFκB pathways (20, 139).  
MYD88 activation of IRF pathways has also been linked directly through TRAF6 (68, 
87).  In the absence of MYD88, the immune response to double stranded RNA, 
unmethylated DNA, and single stranded RNA motifs are ablated demonstrating the 
critical role for MYD88 in TLR signaling (4, 58, 62). 
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 The MYD88-independent pathway relies on the TIR domain containing adaptor-
inducing IFN (TRIF) for downstream signaling(175).  In both TLR3 and TLR4 signaling, 
TRIF acts as an adaptor facilitating activation of TBK-1 and subsequent activation of 
IRF-3. While TLR3 exclusively uses the MYD88-independent pathway, TLR4 utilizes 
both MYD88 dependent and independent pathways to stimulate the immune response to 
infection (3, 66).  Upon binding LPS or a viral ligand, TLR4 stimulates both MYD88 
through interaction with MAL and TRIF through association with the TRIF related 
adaptor molecule (TRAM) to activate pathways leading to NFκB and IRF-3 activation (3, 
86, 199).  Similarly, upon binding double stranded RNA, TLR3 activates TRIF pathways 
leading to downstream signaling (175).  In the absence of TRIF, the induction of IFNβ in 
response to dsRNA or LPS is severely impaired, demonstrating the importance of TRIF 
in inducing MYD88-independent response to virus infection (64).   
 The TLR family has been implicated in the recognition and immune response to 
numerous viruses including HSV-1 both in vivo and in vitro.  In the absence of TLR9,  
plasmacytoid dendritic cells (pDCs) fail to induce type I IFN production in response to 
HSV-1 challenge (100).  HSV-1 glycoproteins have been identified in the activation of 
the TLR2 pathway (7, 171).   TLR3 has been shown to be important for protection 
against herpes simplex encephalitis (HSE) in humans (24, 231).  Yet, in contrast to other 
viruses that encode multiple pathways to interfere with the TLR pathways, very few 
HSV-1 processes have been identified to target TLRs.  ICP0 has been implicated in 
antagonizing TLR signaling through its interaction with USP7 (35).  However, the 
absence of TLR or MYD88 pathways has had minimal impact on HSV-1 replication; in 
fact, the absence of several TLR pathways often resulted in reduced pathology in vivo 
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(100, 102-103).  Together, these results suggest that HSV-1 may be recognized via TLR 
pathways, but it has minimal impact on infection.  Thus, HSV-1 has devoted minimal 
genetic capital to control this pathway. 
 
Intracellular viral recognition pathways 
 Similar to the TLRs, the intracellular pathways of virus recognition utilize pattern 
recognition receptors to recognize PAMPs within the cytoplasm.  The Rig-I like receptor 
family, comprised of retinoic acid inducible gene (RIG-I) and melanoma differentiation 
associated gene 5 (MDA5) recognize elements of viral RNA within the cytosol (18, 54, 
229).   The closely related MDA-5 and RIG-I proteins contain two similar domains: A N-
terminal caspase recruitment domain (CARD) and a C-terminal DExD/H box RNA 
helicase (66).  The C-terminal helicase has been demonstrated to confer RNA binding, 
while the CARD domain is required for interaction with downstream adaptors (66).  
Despite their similar domains, MDA-5 and RIG-I bind distinct RNA motifs resulting in 
recognition of different subsets of viruses.  MDA-5 binds longer molecules of viral 
double stranded RNA and is required for recognition of positive-sense singles including 
norovirus and picornaviruses (54, 120, 195) . In contrast, RIG-I detects single stranded 
RNA sequences with a free 5’ triphosphate or short fragments of double stranded RNA, 
each typically associated with negative-stranded RNA viruses (18, 83, 168).  In the 
absence of either RIG-I or MDA-5,  mice are defective for the induction of type I IFN in 
response to specific viral pathogens.  These results demonstrate the critical role for the 
RLR family in responding to viral challenge. 
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 In addition to the RLR family, additional intracellular pathways have been 
implicated in the recognition of microbial DNA (18).   While the pathways have not yet 
been elucidated, several studies have demonstrated an IFN response to intracellular DNA 
targets (74, 143, 192).  The discovery of a DNA receptor,  DNA-dependent activator of 
IRFs (DAI), suggested a potential mechanism by which DNA recognition occurs (198).  
However, further studies minimize the impact of DAI and suggest additional DNA 
sensors are involved in the immune response (176, 214).    In contrast, another study 
suggests that DNA recognition is mediated through RNA polymerase III conversion of  
DNA to RNA;  the newly formed RNA then activates RIG-I driving production of type I 
IFN (1).   Together, these data provide sufficient evidence to conclude that a DNA 
sensing pathway exists and contributes to the induction of type I IFN in response to virus 
infection. 
 Similar to the TLR pathways, the intracellular pathways are dependent on an 
assortment of adaptors and signaling molecules.   The primary adaptor for the RLR 
family was independently identified by different four groups and given the following 
names: IFNB promoter stimulator 1 (IPS-1),  mitochondrial antiviral signaling (MAVS), 
CARD adaptor inducing IFNB (Cardif), and virus induced signaling adaptor (VISA) (88, 
133, 181, 224).   For the purpose of simplicity, this molecule will be referred to as IPS-1.  
IPS-1 contains an N-terminal CARD domain mediating interaction with the RIG-I and 
MDA-5 (88).   In addition, IPS-1 contains a C-terminal transmembrane domain that 
targets itself to the outer mitochondrial membrane (181).   Upon binding target RNA, 
RIG-I and MDA-5 engage IPS1 resulting in recruitment of several signaling molecules 
including TRAF2, TRAF6, Fas-associated protein with death domain (FADD), and 
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receptor interacting protein 1 (RIP-1)(88, 224).  These signaling molecules activate TBK 
and in turn, lead to the activation of NFκB and IRF pathways, driving production of type 
I IFN. In the absence of IPS-1, the host has a severe defect in RIG-I and MDA-5 
signaling and is susceptible to a variety of RNA virus infections(101).  
 A second adaptor identified as part of the intracellular recognition machinery is 
the stimulator of interferon genes (STING).  STING, an endoplasmic reticulum 
transmembrane protein, has been shown to interact with both IPS1 and RIG-I inducing 
production of type I IFN (75, 194, 234). Further examination revealed that STING is 
necessary for type I IFN production in response to intracellular DNA (76).  In the absence 
of STING, IFNβ production was ablated following challenge with non-CpG DNA; 
STING also contributed to host defense against both RNA and DNA pathogens.  
Together, the data demonstrate a critical role for both STING and IPS-1 in the 
intracellular pathways leading to type I IFN production. 
 Despite their relatively recent discovery , many studies have revealed a variety of 
viruses that target these receptors and adaptors (18).  Through inhibition, cleavage, and 
degradation, viral proteins interfere with the activity of the intracellular recognition 
pathway and delay and inhibit type I IFN production (18, 50, 178).  To date, no HSV-1 
proteins have been directly implicated in antagonizing the RLR or DNA sensing 
pathways.  In fact, the mechanism for HSV-1 recognition is still not fully understood.  
Several studies have demonstrated that HSV-1 induces a MYD88 independent production 
of type I IFN (31, 158).  Additional studies have implicated RIG-I, and STING as 
possible components involved in identification(75, 160) .  Yet, questions remain on the 
exact pathways induced to produce type I IFN following HSV-1 infection. 
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Initiation of type I IFN production 
 IFNβ is among the first type I IFN molecules produced and is critical in the type I 
IFN signaling cascade (45, 202).   Rapidly induced via pathogen recognition pathways, 
IFNβ acts as an autocrine and paracrine activator of the type I IFN receptor, leading to 
amplification of the type I IFN response (156).  In the absence of IFNβ, IFNα subspecies 
fail to compensate, resulting in increased host susceptibility to viral challenge (39, 169).  
Together, the data demonstrate the importance of IFNβ to the immune response to viral 
infection.   
 Regulation of IFNβ production occurs at the gene transcriptional level by 
nucleosome obstruction of the transcriptional start site (2, 66, 114).  Upon viral infection, 
pathogen recognition pathways induce activation of factors that bind to IFNβ promoter 
regions and facilitate nucleosome displacement from the IFNβ transcriptional start site 
(114).  The IFNβ promoter region contains four positive regulatory domains (PRDs): I, 
II, III, and IV (66, 142, 147, 178).  The PRDs bind to transcription factors that are either 
present constitutively or induced by signaling via the type I IFN receptor.  PRD I and III 
bind members of the interferon regulatory factor (IRF) family, notably IRF-3 and IRF-7 
(91). In contrast, PRD II and IV bind nuclear factor kB (NFκB) and AP-1 (a heterodimer 
of activating transcription factor 2 with c-JUN).  Following viral recognition, the 
activated IRFs, NFκB, and AP-1 bind to the PRDs on the IFNβ promoter and recruit the 
high mobility group protein, HMG-1 forming the IFN “enhancesome ”  (91).   The 
enhancesome then recruits histone acetylation transferases (HATs) to aceylate lysine 
residues of histone H3 and H4 in the nucleosome.  Meanwhile, RNA polymerase II is 
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recruited to the promoter and aceylation of the histone results in recruitment of a 
nucleosome modification complex which displaces the nucleosome (2, 66, 114).   
Displacement permits recruitment of TFIID to the IFNβ promoter and induction of IFNB 
follows(2).   Following production, IFNβ then acts in an autocrine and paracrine manner 
initiating the type I IFN cascade in the infected as well as bystander cells (177).  As the 
infection continues, the levels of IFNβ plateau as other forms of type I IFN are produced 
by infiltrating immune cells, most notably variants of IFNα by pDCs (9, 27).   
 
IRF-3 & IRF-7 
In recent years, interferon regulatory factor 3 and 7 have been identified as key 
components of the early recognition response leading to  the type I IFN cascade (18, 66-
67).  IRF-3 is constitutively expressed and located in the cytoplasm of host cells in an 
inactive form (66).   Following stimulation via pathogen recognition pathways, the 
transcription factor undergoes phosphorylation at a serine residue within its C-terminal 
region (134, 180).  Phosphorylation induces dimerization and formation of a homodimer, 
or a heterodimer with activated IRF-7 (196).  The dimer is then transported to the nucleus 
where it binds co-activators CBP and p300 (112).  This complex then targets the IFNβ 
promoter at the PRD I and III sites and facilitates  production of IFNβ (2).  
 In addition, several gene groups have been identified as partially or totally 
dependent on IRF-3 for activation; these genes fall into two categories: genes dependent 
on IRF-3 binding for expression and genes augmented by IRF-3 in the context of type I 
IFN signaling (6, 44, 57).   The IRF-3 augmented group includes several genes primarily 
associated with the immune and interferon response including Rantes, ISG15,  and ISG 
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60 (6).  In contrast, the IRF-3 dependent group includes genes from a variety of 
categories including cell stress, apoptosis and proliferation, in addition to immune 
response genes (6, 44).  A subset of type I IFN, including IFNβ, IFNA4 and IFNa5, are 
among the most notable IRF-3 dependent genes identified.  In the absence of IRF-3, the 
production of IFNβ is severely attenuated both in vitro and in vivo (67, 69).  Together, 
these data demonstrate the importance of IRF-3 in IFNβ production and initiation of the 
type I IFN cascade.  
In contrast to IRF-3, IRF-7 activity is highly dependent on type I IFN signaling.  
IRF-7 is expressed at very low basal levels and has a short half life within the cell (174, 
202).  Upon type I IFN signaling, IRF-7 transcription is strongly induced via the ISGF3 
transcriptional activating complex (173, 202).  In an inactive form, IRF-7 resides in the 
cytoplasm and is phosphorylated on its C-terminal regions upon stimulation by viral 
infection (66).   IRF-7 then forms a homodimer or heterodimer with IRF-3 and 
translocates to the nucleus and activates production of additional type I IFN, primarily 
subtypes of IFNα  (173).  Together, the data demonstrate a critical role for IRF-7 in the 
type I IFN positive feedback look.    
These findings led to a three step model of type I IFN induction (136, 174).  First, 
during the sensitization phase,  viral infection is detected via pathogen recognition 
pathways, leading to IRF-3 phosphorylation and dimerization (18).  Activated IRF-3 
translocates to the nucleus, forms the enchancesome,  and drives expression of IFNβ (91, 
136, 230).  The released IFNβ initiates the second stage of the type I IFN response, the 
inductive phase.  IFNβ acts on both self and bystander cells leading to the expression of 
IRF-7 via signaling through the type I IFN receptor (173).  Viral activity continues to 
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stimulate pathogen recognition pathways leading to IRF-7 activation.  In turn, IRF-7 
leads to further production of type I IFN and provides a positive feedback loop that drives 
the type I IFN cascade.  The continued type I IFN production initiates the final phase of 
the IFN response, amplification.  With production of numerous subset of type I IFN and 
additional IFNAR receptors,  the cell amplifies interferon stimulated genes resulting in 
induction of a full-antiviral state (84, 169). Thus, IRF-3 was thought to govern the initial 
induction of type I IFN and IRF-7 critical to subsequent stages.   
However, in vitro and in vivo studies suggested a less IRF-3 dependent model for 
type I IFN induction (69).  Utilizing deficient mouse embryonic fibroblasts (MEFs), 
IFNβ message was severely decreased in both IRF-3-/- and IRF-7-/- MEFs.  In contrast, 
IFNα message was normal in IRF-3-/- MEFs, but ablated IRF-7-/-  MEFs following 
challenge with EMCV, VSV, and HSV-1.   In either case, the loss of these components 
had no impact on endpoint viral replication (69).  In vivo, intravenous challenge with 
HSV-1 or EMCV resulted in complete lethality in IRF-7-/- mice compared to no  change 
in IRF-3-/- mice compared to control.  Examination of serum revealed a deficit in IFNα 
production in IRF-7-/- mice; no deficit was demonstrated in IRF-3-/- mice following 
intravenous HSV-1 challenge.   
These results led to a revised model that defined IRF-7 as the “master regulator” 
of type I IFN and minimized the impact of IRF-3 (69).  The new model proposes that 
IRF-7, expressed at low basal levels, is activated by viral infection and forms either a 
homodimer or heterodimer with IRF-3 driving production of type I IFN (173-174).  In the 
absence of IRF-3, IRF-7 expression is sustained  by weak activation of ISGF3 through 
spontaneously produced type I IFN (202).     Low level IRF-7 expression partially 
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compensates for the loss of IRF-3, producing sufficient type I IFN to initiate the 
interferon response.  Later,  infiltration of hematopoietic immune cells expressing IRF-7 
constitutively produces sufficient type I IFN to control the infection in vivo (69, 106).  In 
contrast, the loss of IRF-7 results in initial IFNβ production via IRF-3, but no subsequent 
amplification of the type I IFN response (69).  The resulting deficit in type I IFN 
production permits increased lethality in IRF-7 mice following intravenous viral 
challenge.  Together, the data suggest IRF-7 plays a critical role in control of HSV-1 
infection; in contrast, IRF-3 has only a minimal impact during HSV-1 infection both in 
vitro and in vivo.  
However, data from several studies indicate the impacts of IRF-3 and IRF-7 on 
HSV-1 replication may not be so clear.  In the absence of IRF-3 or IRF-7, HSV-1 
replication is unaffected compared to wild-type (WT) cells (69). One possible 
explanation is that IRF-3 is specifically targeted by the virus to prevent induction of the 
immune response.  For example, in the absence of viral gene expression, UV-inactivated 
HSV-1 induces IRF-3 activation and IFN induction to a higher levels than live virus, 
implying manipulation of IRF-3 mediated recognition (31, 158).  HSV-1 ICP0, a 
multifunctional viral antagonist, has been shown to also interfere with IRF-3 activity via 
its N-terminal RING finger domain, an E3 ubiquitin ligase (15, 113).  Studies 
demonstrated that HSV-1 prevents nuclear translocation of IRF-3 following co-infection 
with Sendai virus in an ICP0 dependent manner(126).  Similarly,  ICP0 has been shown 
to recruit IRF-3 and CBP/p300 to nuclear foci away from host chromatin, resulting in 
reduced IFNβ production (128).  In addition, HSV-1 vhs and ICP27 have also been 
implicated in antagonizing the activity of IRF-3 (113, 125).   
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Goals of the Thesis 
In recent years, there has been increased interest in the pathways that induce type 
I interferon in response to viral challenge.  The discovery of RIG-I and the toll like 
receptors initiated examination of the pathogen recognition pathways and led to the 
discovery of new sensors, adaptors, and signaling molecules involved in type I IFN 
induction.  IRF-3 is central to these newly discovered pathways;  it provides a critical 
signaling component required for IFNβ induction and an efficient type I IFN response to 
viral infection.  In the absence of IRF-3, the pathogen recognition pathways would be 
predicted to have delayed and deficient type I IFN production.  The result would be 
increased susceptibility to viral infection. 
The first goal of this thesis was to fully evaluate the impact of IRF-3 dependent 
pathways on HSV-1 replication in vitro.  IRF-3 has been shown to play a critical role in 
the type I IFN cascade initiated by the early pathogen recognition pathways.  Therefore, 
the loss of IRF-3 was predicted to impact the type I IFN response resulting in increased 
viral replication in vitro. However, the loss of IRF-3 had been previously shown to have 
no impact on viral replication in mouse embryonic fibroblast (MEFs), thus implying a 
minimal role for IRF-3 in the IFN response to HSV-1.  Yet, HSV-1 entry has been shown 
to activate IRF-3 and the virus encodes viral proteins that antagonize IRF-3 activity; 
together, these results suggest that IRF-3 does impact HSV-1 infection.  In order to 
address this apparent contradiction,  immune cells lacking IRF-3 were challenged with 
HSV-1 in vitro.  Immune cells were predicted to have a more vigorous immune response 
and the impact of IRF-3 on HSV-1 infection might be more discernable in these cell 
types. 
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The second goal of the thesis was to determine the role of IRF-3 on in vivo HSV-1 
infection.  IRF-3 had been previously shown to have no impact on survival following 
intravenous infection with HSV-1.  However, intravenous challenge likely bypasses the 
physiologically relevant cell types for  alphaherpesvirus infection: the epithelia and 
neurons.  Therefore, examination of the IRF-3 deficient mice via the ocular route of 
infection permits evaluation of viral replication, trafficking of the virus, and the 
establishment of latency in vivo.  Intracranial challenge with HSV-1 permits examination 
of lethality and viral fitness in the CNS.    
The final goal of the thesis was to determine the pathways involved in recognition 
of HSV-1.  While IRF-3 signaling has been implicated in sensing HSV-1 infection in 
vitro, the recognition pathway utilized by the host has not been identified.  In order to 
determine the pathways involved in HSV-1 recognition, immune cells and mice lacking 
components of the RLR, TLR, and DNA sensing pathway were challenged with HSV-1.  
The loss of one or more of these components would be predicted to have a significant 
impact HSV-1 replication in vitro or in vivo.  
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Chapter II 
 
 
Control of herpes simplex virus replication is mediated through an 
IRF-3 dependent pathway. 
 
 
This chapter contains data published in the following  publication: 
 
Menachery, V. D., and D. A. Leib. 2009. Control of herpes simplex virus replication is 
mediated through an interferon regulatory factor 3-dependent pathway. J Virol 83:12399-
406. 
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ABSTRACT 
Type I Interferon (IFN) cascade is critical in controlling viral replication and 
pathogenesis.  Recognition pathways triggered by viral infection rapidly induce the type I 
IFN cascade, often in an interferon regulatory factor 3 (IRF-3)-dependent fashion.  This 
dependence predicts that loss of IRF-3 would render early recognition pathways 
inoperative and thereby impact virus replication, but this has not been observed 
previously with HSV-1 in vitro. In this study, HSV-1 infected IRF-3-/- bone marrow-
derived dendritic cells (BMDCs) and macrophages (BMM) supported increased HSV-1 
replication compared to control cells.   In addition, IRF-3-deficient BMDCs exhibited 
delayed type I IFN synthesis compared to control cells. However, while IFN pretreatment 
of IRF-3-/- BMDCs resulted in reduced viral titers, a far greater reduction was seen 
following IFN treatment of wild-type cells. This suggests that even in the presence of 
exogenously supplied IFN, IRF-3-/- BMDCs are inherently defective in control of HSV-1 
replication.  Together, these results demonstrate a critical role for IRF-3 mediated 
pathways in controlling HSV-1 replication in cells of the murine immune system. 
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INTRODUCTION 
Herpes simplex virus type I (HSV-1) is a ubiquitous human pathogen with high 
seroprevalence in adults (51).   HSV-1 is associated with numerous human diseases 
ranging from the common cold sore in immune-competent individuals, to herpetic 
encephalitis in neonatal and immunocompromised hosts.  A member of the 
Alphaherpesvirus family, HSV-1 exhibits two distinct phases of infection (49).  Acute 
infection typically occurs at peripheral epithelial sites and is characterized by lytic 
infection and spread.  In contrast, the virus shifts from lytic to latent infection in sensory 
neurons which is characterized by limited gene expression and the persistence of viral 
genomes in a transcriptionally active state. Following certain stimuli, periodic 
reactivation of latency occurs, and may result in shedding of infectious virus at the initial 
site of acute infection.  Reactivation may also be associated with immunopathological 
diseases, most notably ocular herpetic stromal keratitis.   
A role for interferons (IFNs) in controlling viral replication is well-established.  In 
recent years, viral research has focused on cellular recognition of pathogen-associated 
molecular patterns (PAMPs) and subsequent IFN induction, leading to the discovery of 
toll-like receptors (TLRs) and retinoic acid inducible gene 1 (RIG-I) -like sensing 
molecules (18). Such molecules respond to several virally-derived PAMPs. These include 
MDA-5 and TLR-3 which recognize double-stranded RNA (13, 24), DAI and TLR-9 
which recognize double-stranded DNA (14, 45),  TLR-7 which recognizes single-
stranded RNA (9), and RIG-I which recognizes triphosphate and double-stranded RNA 
(16, 31, 53).  Subsequent work identified the adaptor molecules necessary for antiviral 
pathway signaling, including MyD88, TRIF and IPS-1 (19, 46, 52).  Not surprisingly, 
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numerous gene products from viruses such as HCV, WNV, influenza and vaccinia have 
been identified to antagonize these pathways and serve to promote viral replication and 
virulence by degradation, interference, or sequestration of early recognition components 
(3, 11).   
These newly-identified recognition pathways utilize IRF-3, IRF-7 and NFκB to 
induce IFN transcription through cognate binding sites on the IFN-β promoter (38).  
During initial induction of IFN, IRF-3 and NFκB, which are constitutively expressed, 
become activated and translocate to the nucleus where they bind the IFN-β promoter to 
form the IFN enhancesome (54).   The initial IFN-β produced acts upon the IFNαβ 
receptor (IFNAR) in both an autocrine and paracrine manner to up-regulate interferon 
stimulated genes (ISGs), most notably IRF-7 (38).  In concert with IRF-3, IRF-7 
amplifies and facilitates expression of the full type I IFN cascade.  In the absence of IRF-
3, IFN-β production is reduced but IFN-α levels remain normal, suggesting that IRF-7 
activity can compensate for the loss of IRF-3 (15).  In contrast, IRF-7 deficiency results 
in significant reduction in serum IFN levels with a corresponding increase in 
susceptibility to virus infection.  IRF-7 was therefore dubbed “the master regulator” of 
type I IFN-dependent immune responses (15).  IRF-7-/- mice challenged with HSV-1 
showed increased mortality compared to control and IRF-3-/- mice, but no increases in 
viral titers were observed in IRF-3- or IRF-7-deficient cells in vitro (15). A possible 
explanation for this lack of phenotype in vitro is that HSV-1 may control IRF-3 activation 
so thoroughly that this pathway is neutralized during infection. UV-inactivated HSV-1 
induces IRF-3 dimerization and activation, leading to IFN induction, suggesting that very 
early events in infection are responsible for triggering this cascade in the absence of viral 
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gene expression (6, 23). ICP0, an immediate early gene of HSV-1, interacts with IRF-3 
and plays a critical role in preventing the induction of the IFN response (10, 23, 27, 28, 
30, 42). Additional HSV genes such as the virion host shut-off protein, ICP34.5, and 
ICP27 also interfere with the activity of IRF-3 (23, 26, 48).   However, the increased 
susceptibility of IFN receptor knockout mice to HSV-1 compared to wild type mice 
suggests that despite so many genes regulating this pathway, the virus does not maintain 
total control over the type I IFN cascade (22, 32).  In addition, numerous recognition 
molecules have been implicated in HSV-1 identification and the subsequent immune 
response (for example TLR-3, TLR-2, TLR-9, RIG-I), but the loss of any of these 
components does not result in any significant increase in viral replication in vitro (21, 35, 
37, 55). 
In these studies, we examined the impact of IRF-3 mediated pathways on HSV-1 
replication using cells from IRF3-deficient (IRF-3-/-) mice.  The absence of IRF-3 was 
predicted to preclude the function of early recognition pathways and thereby impact 
HSV-1 replication. No changes in HSV-1 replication in IRF-3-deficient mouse 
embryonic fibroblasts (MEFs) had been observed previously, but we reasoned that 
relative to MEFs, cells of the immune system might induce more vigorous IRF-3-
dependent antiviral responses, manifesting with a significant impact upon viral 
replication. Using IRF-3 deficient bone marrow-derived dendritic cells (BMDCs) and 
macrophages (BMM) we have demonstrated that IRF-3 mediated pathways are critical 
for control of HSV-1 replication. Moreover, control of HSV-1 replication is dependent on 
the type I IFN cascade in these cell types induced via IRF-3 mediated pathways. 
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METHODS 
Cells and viruses. Viral stocks were grown and titers were determined on Vero cells 
(34). HSV-1 wild-type strain KOS was the background strain for this study (41).  
BMDCs were generated from 6-8 week old C57BL/6 (Charles River Laboratories, 
Willmington, MA) or 129S6 (Taconic, Germantown, NY) mice (25, 56). Briefly, bone 
marrow was flushed from femurs of mice and cells were cultured as described below.  
For generation of BMDCs, bone marrow was cultured in RPMI with 10% fetal calf 
serum, Glutamax, Na pyruvate, non-essential amino acids, 250 U/ml penicillin, 250 U/ml 
streptomycin, and 2% GM-CSF for 6-8 days at 37°C. BMDCs were then collected, 
counted, and aliquoted for infection at several MOIs by the addition of virus in a minimal 
volume of medium for 30 minutes at 37°C.  Cells were then spun at low speed, inocula 
removed, washed, resuspended, and plated in 35-mm wells for the duration of the 
experiment. BMDCs were also generated from mice deficient in IRF-3-/- (15), IRF-7-/-
(15), STAT-1-/- (29) (Taconic, Germantown, NY),  IFN-αβγ R-/- (AG129)  (47). 
Bone marrow macrophages were cultured as described (56). Briefly, bone marrow 
was cultured in DMEM supplemented with 10% fetal calf serum, 5% heat-inactivated 
horse serum, 20% L-929 conditioned medium, 250U/ml penicillin, 250U/ml streptomycin 
for 7 days on non-tissue culture treated plates.  At day 7, cells were washed with a 0.02% 
EDTA solution, collected, and counted.  The cells were plated in 35-mm wells and rested 
for three days.  The BMM were infected at MOIs of 0.01 and 1 by the addition of virus in 
a minimal volume of medium for 30 minutes at 37°C, removal of inoculum, and followed 
by the addition of complete medium.   
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IFN-β ELISA.  Bone marrow-derived dendritic cells were mock-treated or infected at an 
MOI of 5 with HSV-1 and cultured in 1 ml of medium.  Cultured supernatants were 
harvested at 3, 6, 9, and 12 hours post infection and spun at low speeds to remove cells.  
Supernatants were stored at -20°C before assay of IFN-β in the medium using 50 µl of 
harvested medium in a mouse IFN-β enzyme-linked immunosorbent assay (ELISA) as 
described in the kit protocol (PBL Biomedical Laboratories, Piscataway, NJ). 
Antibody blockade.  MAR1-5A3, an IgG1 monoclonal antibody specific to the IFN-α 
receptor (Leinco Technologies, St. Louis, MO) was utilized as described (39).  Briefly, 
after infection, cells were plated in 1 ml of complete medium with 5μg/ml of MAR1-5A3 
for the duration of the experiment.  At specified times, cells were harvested and titered on 
Vero cells under methylcellulose. 
Mixing Experiment.  BMDCs were collected, counted, and aliquoted for infection. WT 
and IRF-3-/- BMDCs were mixed at a ratio of 1:1 such that cell numbers equaled those of 
non-mixed controls.  The mixed and non-mixed populations were then immediately 
infected as previously described.   
IFN-β pretreatment.  BMDCs were treated for 16 hours with 100 U/ml mouse IFN-β 
(PBL Biomedical Laboratories, Piscataway, NJ) or mock in PBS. BMDCs were then 
collected, counted, and aliquoted for infection as previously described.  No additional 
IFN-β was added after infection.  
Statistics.  All statistical calculations were determined by Student’s t test and are relative 
to control cells unless otherwise stated. 
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RESULTS 
Control of HSV-1 replication in BMDCs is IRF-3-dependent in vitro.  A previous 
study using IRF-3- and IRF-7-deficient MEFs demonstrated that the absence of either 
signaling molecule did not significantly alter HSV-1 replication (15).  Work performed in 
this laboratory is in agreement with these previous observations (Fig. 2.1).  Additional 
experiments with IRF-3/IRF-7 double deficient MEFs also demonstrated no change in 
HSV-1 replication (Fig. 2.2).   BMDCs were chosen for infection in this study due to 
their function as immune sentinels, their strong responses to IFN, and their critical role in 
controlling HSV-1 infection in vivo (17, 43, 44).  IRF-3-/- BMDCs yielded at least 10 
times more HSV-1 replication than control cells at both 24 and 48 hours post infection at 
each MOI tested (Fig. 2.3). In contrast, HSV-1-infected IRF-7-/- BMDCs did not yield 
any increased viral titers compared to wild-type control BMDCs.  These results suggested 
that pathways for control of HSV-1 replication in BMDCs are dependent on IRF-3, but 
independent of IRF-7.  
 
BMM require IRF-3 for control of HSV-1 replication. Primary bone marrow 
macrophages were infected in order to further assess the role of IRF-3 mediated pathways 
in immune cells (2, 5).  These adherent BMMs were also tested to exclude the possibility 
that the replication pattern of HSV differed between MEFs and BMDCs because of their 
adherence and non-adherence to plastic substrates in culture.  The results, however, 
demonstrated that the pattern of viral replication in the IRF-3-/- BMMs resembled that 
seen in BMDCs, with increased viral yields as compared to control cells (Fig. 2.4). 10- to 
100-fold increases in viral yields were demonstrated at both 24 and 48 hours post 
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infection at MOIs of 0.01, 1, and 5 (data not shown). Interestingly, IRF-7-/- BMM also 
supported increased viral replication.  In contrast to BMDCs, IRF-7 deficient BMMs 
permitted a 10- to 100-fold increase in viral replication compared to controls at 24 and 48 
hours post infection.  This increase in viral titers was greater in magnitude at the lower 
MOI, but the impact of IRF-7 loss on HSV replication in BMMs was less than the impact 
of loss of IRF-3. These data suggest a role for both IRF-3 and IRF-7 in control of HSV-1 
replication in BMM.  BMDCs, however, have no requirement for IRF-7 in controlling 
HSV-1 replication, demonstrating difference in the innate immune response between 
macrophages and dendritic cells.  Overall, in both cell types, IRF-3 mediated pathways 
are required to control HSV-1 replication in vitro.  
 
BMDCs lacking interferon receptors permit increased viral replication in a STAT-1 
dependent manner. Having identified a role for IRF-3 mediated pathways in controlling 
HSV-1 replication in BMDCs and BMMs, focus was shifted to differentiating between 2 
non-mutually exclusive mechanisms by which IRF-3 could be controlling HSV-1 
replication.  First, it is possible that IRF-3-/- BMDCs have delayed or reduced type I IFN 
responses, disrupting the type I IFN cascade, and resulting in increased viral replication.  
Second, it is possible that other IRF-3-dependent processes or gene products are directly 
controlling HSV-1 replication.  To address these possibilities, BMDCs lacking both Type 
I and Type II IFN (αβ and γ receptors) were infected with HSV-1 (Fig. 2.5).  These cells 
lack IFN binding and signaling, but contain IRF-3, and thereby maintain elements of the 
early recognition pathway via IRF-3 dependent gene expression.  The IFN receptor-
deficient BMDCs permitted increased viral growth in a similar fashion to IRF-3-/- 
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BMDCs and suggested that the type I IFN cascade was responsible for controlling HSV-1 
replication (Fig. 2.4). Similar increases in viral replication were also seen in STAT-1-/- 
BMDCs. Together, these data confirm that viral replication is significantly limited in 
these cell types through IFN-driven STAT-1 signaling. While these data do not 
completely exclude other IRF-3 dependent processes, the results strongly suggest that the 
increased viral yields in IRF-3-/- BMDCs and BMMs are due to a delayed or defective 
type I IFN cascade. 
 
IRF-3 deficient BMDCs have a defect in IFN-β induction compared to WT control 
cells.  IFN-β plays a critical role in inducing an antiviral state and controlling viral 
infection (18).  A deficit or a delay in IFN-β induction would likely allow increased viral 
replication, as seen in IRF-3-/- BMDCs.  In order to examine this question, IFN-β protein 
levels were determined by ELISA in control and IRF-3-/- BMDCs following infection 
with HSV-1 (Fig. 2.6). BMDCs were infected at an MOI of 5 to ensure uniform infection 
and minimize the contribution of bystander IFN.  Even at this high MOI, IRF-3-/- BMDCs 
yielded a statistically significant increase in HSV-1 titer at 12 and 24 hours post 
infection. Examining IFN-β protein, IRF-3-/- BMDCs exhibited decreased and delayed 
IFN-β production relative to wild-type control BMDCs.  WT BMDCs produced 
detectable levels of IFN-β as early as six hours post-infection and continued to escalate at 
nine and twelve hours post infection.  In contrast, IRF-3 deficient BMDCs only produced 
measurable levels at twelve hours post-infection, suggesting a defect in the initiation of 
IFN-β production. The IRF-3-/- BMDCs were, however, capable of producing IFN-β late 
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in the experimental infection, thereby potentially allowing control of viral replication at 
these later times. 
 
IFNαR-blocking antibody augments viral growth in wild-type control and IRF-3- 
deficient BMDCs. To demonstrate that production of type I IFN was a primary defect, 
WT and IRF-3-/- BMDCs were infected and then treated with antibodies that block the 
IFN-α receptor (IFNαR) or control IgG1 antibody (Fig. 2.7 and data not shown).  We 
postulated that if the restriction of HSV-1 replication in this system was dependent on 
type I IFN induction then WT and IRF-3 deficient BMDCs should yield similar viral 
titers in the presence of the blocking antibody. Control IgG1 had no impact on viral 
replication in either cell type (data not shown).   In contrast, the addition of IFNαR 
blocking antibodies allowed both wild-type and IRF-3-/-  BMDCs to produce higher 
yields of HSV-1 such that viral growth curves for these two disparate cell types were 
similar under these conditions  (Fig. 2.7). It was also notable that untreated IRF-3-/- 
BMDC cultures yielded similar titers as antibody-treated BMDCs at 24 hours post 
infection. In contrast, by 48 hours post infection, antibody-treated IRF-3-/- BMDCs 
yielded 10-fold more virus than untreated cultures.   Together, these data demonstrate 
that the type I IFN cascade is responsible for controlling HSV-1 replication in wild-type 
BMDCs, and that at late time points, IRF-3-deficient BMDCs can exert partial type I 
IFN- dependent control of HSV-1 replication.  
 
IFN induction from wild-type BMDCs fails to restore control of HSV-1 replication 
to IRF-3 deficient BMDCs in vitro.  The preceding data suggested that IFN induction 
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was defective in IRF-3 deficient BMDCs, but that these cells were still capable of 
controlling viral infection once the type I IFN cascade had been initiated.  The question 
arose therefore, if the initial IFN induction and synthesis were restored, could IRF-3-/- 
BMDCs limit HSV-1 replication to levels seen in wild-type control cells? We therefore 
investigated whether bystander IFN, produced by WT cells, could restore control of viral 
replication to IRF-3-/- BMDCs by mixing them in culture at a 1:1 ratio.  The mixed cell 
population was then infected with HSV-1 at an MOI of 0.01 and viral replication 
measured (Fig. 2.8).  Viral growth kinetics under these conditions were intermediate 
between those observed in wild-type (low viral growth) and IRF-3-/- (high viral growth) 
BMDCs. At 48 hours post infection, the mixed BMDC population gave a 10-fold 
increase in viral yield over wild-type cells alone, and a 10-fold decrease in viral yield 
over IRF-3-/- BMDCs alone. The results show that IRF-3-/- BMDCs are incapable of 
controlling viral replication even in the presence of bystander IFN induced by viral 
infection of WT cells. Another possibility, although less likely, is that the presence of 
IRF-3-/- BMDCs resulted in a reduced total type I IFN concentration thereby permitting 
increased replication in WT BMDCs.  In either case, HSV-1 replication of IRF-3 
deficient BMDCs was not limited in the context of bystander cell-produced IFN.  
 
IRF-3 deficient BMDCs primed with IFN partially restore control of HSV-1 
replication. The results from the cell mixing experiments suggested that IRF-3-/- BMDCs 
were unable to respond fully to IFN production by WT cells.   However, the ability to 
generate a delayed IFN-β response coupled with the IFN-dependent decrease in viral 
titers at late time points suggested that IRF-3-/- BMDCs were capable of inducing the type 
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I IFN cascade, but with low efficiency.  One possible model is that cells lacking IRF-3 
are inherently slowed in their response to IFN, and need additional time to properly prime 
in order to fully control HSV-1 replication in vitro.  To test this, WT and IRF-3-/- BMDCs 
were pretreated overnight with IFN-β, challenged with HSV-1, and viral yields measured 
(Fig. 2.9).  IFN pre-treatment of IRF-3-/- BMDCs significantly decreased HSV-1 
replication as compared to untreated IRF-3-/- cells with a greater than 100-fold decrease in 
viral titers at 48 hours post infection.  Titers observed were comparable to those in 
untreated WT control BMDCs.  However, pretreatment of WT control cells resulted in 
further decreases in viral replication, to levels at, or below, the level of detection.  These 
results together suggest that IRF-3 deficient BMDCs were capable of strongly responding 
to IFN, but the overall immune response in controlling HSV-1 replication was still 
defective compared to WT control cells.  
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DISCUSSION 
Despite mice or cells lacking IFN receptors being significantly more susceptible 
to viral infection (22, 32), loss of IRF-3 and IRF-7 had surprisingly little impact on HSV-
1 replication in vitro (15). Several groups have suggested the lack of a growth phenotype 
in IRF3-/- cells may be due to HSV-1 maintaining strict control over IRF-3-dependent 
pathways through various viral genes including ICP0, ICP27, ICP34.5 and vhs, thereby 
neutralizing the impact of IRF-3 mediated pathways (6, 10, 23, 26-28, 30, 35, 42).  In this 
study, we have demonstrated that HSV-1 replication was controlled in an IRF-3- 
dependent manner in two types of immune cells.  This control was dependent on type I 
IFN and STAT-1 signaling with a primary defect in IFN production in IRF-3-/- cells.  
Even in the presence of exogenously-supplied IFN, however, HSV-1 replication was only 
partially controlled in IRF-3-/- BMDCs.  Overall, the data presented provide evidence that 
IRF-3 mediated pathways have a significant impact on HSV-1 replication in certain cell 
types.   
Previous studies examining HSV-1 and IRF-3-/- used highly permissive MEFs, 
whereas in this study dendritic cells and macrophages were chosen.  Given the roles of 
dendritic cells and macrophages as sentinels of the immune system capable of controlling 
viral infection in vivo, it is likely that these cells induced a more vigorous immune 
response and were thereby less permissive to infection than MEFs (2, 5, 17, 43, 44). In 
the case of HSV, a virus with multiple mechanisms to subvert IFN responses, loss of 
IRF-3 can only manifest with increased viral titers in cells that respond strongly to IFN.  
This idea is supported by studies with West Nile virus (WNV) (12).  Only at late time 
points, IRF-3-/- MEFs support nearly a 4 log increase in WNV titers compared to control 
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cells suggesting robust IRF-3 dependent responses in control MEFs late in infection.  In 
contrast, examination of WNV in bone marrow macrophage cultures demonstrated 
increased viral replication in IRF-3-/- BMM immediately, as early as 24 hours post 
infection, and continued through 72 hours post infection (7). A similar difference in viral 
replication between MEFs and immune cells was reported with mouse norovirus (MNV) 
in the context of STAT-1 deficiency (50). These data support the hypothesis that immune 
cells have a more vigorous antiviral response than MEFs and loss of IRF-3 on viral 
replication may be more accurately measured in more restrictive immune cell types.  This 
hypothesis is especially relevant to HSV-1, which relative to WNV and MNV, has more 
genes for IFN regulation, produces less dsRNA, and exhibits less sensitivity to type I 
IFN.    
Not surprisingly, in the absence of IRF-3, BMDCs and BMM were unable to 
efficiently control HSV-1 replication (Figs. 2.3 and 2.4).  While the IFN receptors are 
intact in these cells, the early recognition signaling likely cannot proceed efficiently 
without IRF-3, leading to a delay in the type I IFN cascade.  Later, once secondary 
rounds of infection have begun, alternate recognition pathways, most likely mediated 
through IRF-7, can lead to the induction of type I IFN.  This recognition by a secondary 
pathway is supported by the observed late production of IFN-β (Fig. 2.6) and the 
concomitant decreased viral replication in IRF-3-/- BMDCs at late time points (Fig. 2.7).   
While IRF-3 is constitutively expressed in both BMDCs and BMM, basal expression of 
IRF-7 varies according to cell type (33).  Plasmacytoid dendritic cells (pDCs) 
constitutively express IRF-7 while IRF-7 expression is reduced in conventional BMDCs 
as compared to IRF-3.  BMMs  exhibited basal expression of both IRF-3 and IRF-7, 
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potentially explaining increased replication in IRF-7-/- BMM but not in IRF-7-/- BMDCs 
(8).  Those studies observed a parallel trend in WNV replication in IRF-7-/- BMM and 
BMDCs as seen here with HSV-1. Yet, in both cell types, the presence of IRF-7 cannot 
compensate for the loss of IRF-3 mediated pathways.  These results suggest that IRF-3 
mediated pathways provide the major pathway of control of HSV-1 replication.     
Together, our results demonstrate that the early recognition response through IRF-
3- mediated pathways controls HSV-1 replication in BMDCs and lead to the following 
model (Fig. 2.10).  Upon virus entry, an as-yet undetermined sensor recognizes HSV-1 
and triggers a signaling cascade that activates IRF-3.  IRF-3 activation leads to 
production of IRF-3 dependent gene products, type I IFN, and an ensuing type I IFN 
cascade, resulting in control of HSV-1 infection.  In the absence of the type I IFN 
cascade, achieved by knockout (Fig. 2.5) or receptor blockade (Fig. 2.7), BMDCs are 
unable to control viral replication.  Similarly, ablating IRF-3 and the early recognition 
response results in increased viral replication due to delayed and reduced IFNβ 
production (Fig 2.3, 2.4, 2.6).  Exogenous IFN provided by bystander cells (Fig. 2.8)  or 
pretreatment (Fig. 2.9) partially restores control of HSV-1 replication in IRF-3-/- 
deficient BMDCs,  yet these cells remain defective in their control of HSV-1 replication 
compared to treated WT cells. 
Several non-mutually exclusive possibilities exist to explain this persistent defect 
in the ability of IRF-3-/- BMDCs to control HSV-1 replication (Fig. 2.10, white squares). 
One possibility is a defective autocrine and paracrine IFN amplification response.  While 
wild-type BMDCs quickly respond to IFN through STAT-1 and IRF-3 signaling 
pathways, IRF-3-/- BMDCs can only respond through STAT-1-dependent, IRF-3-
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independent pathways.  The absence of IRF-3 thereby severely decreases or ablates the 
expression of several gene products, including IFN-β, IFNα4 and IFNα5 (1), resulting in 
less robust IFN signaling.  A second possibility is that IRF-3 dependent ISGs synergize 
with Type I IFN receptor dependent ISGs and control HSV-1 replication, but fail to be 
produced robustly in IRF-3-/- BMDCs. A third possibility is that virus recognition may be 
required to augment the ongoing immune response.  IFN primed IRF-3-/- BMDCs may 
produce IFN effectors, but a lack of viral recognition signaling results in a delayed 
effector response from ISGs.  IRF-3-/- BMDCs may therefore require HSV-1 recognition 
signaling through a secondary pathway before fully committing to a complete IFN 
effector response, and this delay could result in the observed increased viral replication, 
compared to wild-type controls.  
Together, these data demonstrate that immune cells lacking IRF-3 are inherently 
defective in the control of HSV infection. These data, however, conflict with previously 
published in vivo data following intravenous (IV) infection (15).  A possible explanation 
is that following IV infection, IFN was being produced by plasmacytoid dendritic cells 
(pDCs).  pDCs, typically found in the lymph nodes away from the site of infection, are a 
major producer of type I IFN, and they rely on TLR-9 and IRF-7 pathways to induce IFN 
in response to HSV-1(4, 20, 40).  Following IV infection, therefore, pDC production of 
type I IFN likely overcomes the IFN deficit and thereby is able to control HSV-1 
replication in the absence of IRF-3.  Previous in vitro studies in MEFs suggested a role 
for HSV-1 gene components in interfering with and neutralizing the activity of IRF-3 (10, 
23, 26-28, 30, 36, 42, 48).  In the cell types used in this study, heightened immune 
responses likely reduced the efficacy of one or more viral immuno-regulatory 
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components, or presented too great of a challenge for the viral activities to counter. 
Therefore, the efficacy of HSV-1 genes in antagonism of IRF-3 likely depends on the 
overall capacity of the infected cell to mount an immune response to the incoming virus.  
Ongoing experiments in our laboratory seek to determine the precise molecules 
responsible for HSV-1 recognition. As mentioned previously, several candidates in the 
early recognition pathways have been implicated (21, 35, 37, 55) and cells lacking these 
components are currently being tested for their ability to control viral replication in 
BMDCs.  Furthermore, in vivo studies in IRF-3 deficient animals are currently underway 
in order to examine HSV-1 replication and pathogenesis in peripheral and neuronal 
tissues. 
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Figure 2.1. In vitro replication in mouse embryonic fibroblasts.  Primary MEFs were 
infected with wild-type HSV-1 at an MOI of 1 or 0.01.  At indicated times post infection, 
cells and supernatants were harvested and viral titers assayed on Vero cells.  Results 
shown are mean titers of three independent experiments. 
 
Figure 2.2.  In vitro replication in double deficient mouse embryonic fibroblasts. 
Primary MEFs lacking IRF-3 and IRF-7 were infected with wild-type HSV-1 at an MOI 
of 5, 1, or 0.01.  At indicated times post infection, cells and supernatants were harvested 
and viral titers assayed on Vero cells.  Results shown are mean titers of three independent 
experiments. 
 
Figure 2.3.  In vitro replication in bone marrow derived dendritic cells.  Primary 
BMDCs were infected with wild-type HSV-1 at an MOI of 1 or 0.01.  At indicated times 
post infection, cells and supernatants were harvested and viral titers assayed on Vero 
cells.  Results shown are the mean titers of three independent experiments.  *p value 
<0.05 **p value <0.01.  
 
Figure 2.4. In vitro replication in bone marrow derived macrophages.  Primary BMM 
were infected with wild-type HSV-1 at an MOI of 1 or 0.01.  At indicated times post 
infection, cells and supernatants were harvested and viral titers assayed on Vero cells.  
Results shown are mean titers of four independent experiments. *p value <0.05 **p value 
<0.01***p value<0.001.  
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Figure 2.5. In vitro replication in BMDCs lacking IFN signaling.  Primary BMDCs 
derived from wild-type, IFNαβγ Receptor deficient (AG129) or STAT-1 deficient mice 
were infected with wild-type HSV-1 at an MOI of 1 or 0.01.  At indicated times post 
infection, cells and supernatants were harvested and viral titers assayed on Vero cells.  
Results shown are the mean titers of three independent experiments.  *p value <0.05 **p 
value <0.01***p value<0.001. 
 
Figure 2.6. IFN-β secretion by infected BMDCs.  Primary BMDCs were infected with 
wild-type HSV-1 at an MOI of 5.  At indicated times post infection, cells and 
supernatants were harvested.  Cells were removed by low speed centrifugation and 
supernatants were assayed for IFN-β by ELISA.  Results are shown in pg/mL and are 
mean totals from three independent experiments. Cells and supernatants were also 
assayed for viral titers at 6, 12, and 24 hours post infection and viral titers were assayed 
on Vero cells.  Results shown are the mean titers of three independent experiments.   *p 
value <0.05   
 
Figure 2.7. IFNαR blockade in BMDCs.  Primary BMDCs were infected with wild-
type HSV-1 at an MOI of 0.01.  Following infection, BMDCs were plated in media 
containing 5μg/mL IFNαR blocking antibody (MAR1-5A3) for the duration of the 
experiment.  At indicated times post infection, cells and supernatants were harvested and 
viral titers assayed on Vero cells.  Results shown are the mean titers of three independent 
experiments.   *p value <0.05 **p value <0.01.  
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Figure 2.8. In vitro replication following mixing BMDC populations.  Primary WT 
and IRF-3-/- BMDCs were mixed at a 1:1 ratio and infected at an MOI of 0.01.  At 
indicated times post infection, cells and supernatants were harvested and viral titers 
assayed on Vero cells.  Results shown are the mean titers of three independent 
experiments.  *p value <0.05. 
 
Figure 2.9. In vitro replication following IFN-β pretreatment of BMDCs.  Primary 
WT and IRF-3-/- BMDCs were pretreated with 100U/mL mouse IFN-β for 16 hours.  
Cells were then infected with WT HSV-1 at an MOI of 0.01. At indicated times post 
infection, cells and supernatants were harvested and viral titers assayed on Vero cells.  
Results shown are the mean titers of three independent experiments. *p value <0.05 **p 
value <0.01.  
 
Figure 2.10. Model for continued defect in IRF-3 deficient BMDCs. Post attachment, 
HSV-1 infection is recognized through an unknown sensor mechanism that leads to 
activation of IRF-3.   The early recognition pathway mediates production of type I IFN 
and IRF-3 dependent interferon stimulated genes leading to the control of HSV-1 
replication via the type I IFN cascade. However, pretreatment with IFN does not restore 
HSV-1 replication in IRF-3-/- BMDCs to WT levels. The continued defect is potentially 
due to three, non-exclusive mechanisms outlined in white squares: defective IFN 
amplification, defective antiviral trigger signaling, and IRF-3 dependent gene synergy 
with the antiviral response.  One or more of these mechanisms leads to continued defect 
in the control of HSV-1 replication in IRF-3-/- BMDCs as compared to WT BMDCs after 
IFN treatment.
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Figure 2.1.  In vitro replication in mouse embryonic fibroblasts.   
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Figure 2.2.  In vitro replication in double deficient mouse embryonic fibroblasts. 
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Figure 2.3.  In vitro replication in bone marrow derived dendritic cells. 
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Figure 2.4.   In vitro replication in bone marrow derived macrophages.   
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Figure 2.5.   In vitro replication in BMDCs lacking IFN signaling.   
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Figure 2.6.  IFN-β secretion by infected BMDCs.   
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Figure 2.7.  IFNαR blockade in BMDCs.   
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Figure 2.8.  In vitro replication following mixing BMDC populations.   
 
 
 
 
 
 
 
 
 
 
77 
 
Figure 2.9.  In vitro replication following IFN-β pretreatment of BMDCs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
78 
 
Figure 2.10.   Model for continued defect in IRF-3 deficient BMDCs. 
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ABSTRACT 
The initiation of the immune response at the cellular level relies on specific recognition 
molecules to rapidly signal viral infection via interferon (IFN) regulatory factor-3 (IRF-3) 
-dependent pathways.  The absence of IRF-3 would be expected to render such pathways 
inoperative and thereby significantly impact viral infection.  Unexpectedly, previous 
studies found no significant change in herpes simplex virus (HSV) pathogenesis in IRF-3-
/- mice following intravenous HSV-1 challenge (Honda, K., et al.,  Nature 2005, 434:772-
777). In contrast, the present study demonstrated that IRF-3-/- mice are significantly more 
susceptible to HSV infection via the corneal and intracranial routes. Increased viral 
replication and inflammatory cytokine production were observed in brain tissues of IRF-
3-/- mice compared to control mice, with a concomitant deficit in production of both IFNβ 
and IFNα.   These data demonstrate a critical role for IRF-3 in control of central nervous 
system infection following HSV-1 challenge. Furthermore, this work underscores the 
necessity to evaluate multiple routes of infection and animal models in order to fully 
determine the role of host resistance factors in pathogenesis.  
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INTRODUCTION 
Herpes simplex virus type I (HSV-1) is a ubiquitous pathogen of the alphaherpesvirus 
family with high seroprevalence in the adult human population (64).  Possessing two 
distinct phases, HSV-1 causes a life-long infection with an initial lytic stage followed by 
a shift to latency following trafficking to sensory neurons (63).  Periodically, reactivation 
from latency occurs and is associated with numerous diseases ranging from the common 
cold-sore to ocular herpetic stromal keratitis (HSK), a leading cause of infectious 
blindness (25, 47).  Reactivation events as well as primary infections are associated with 
herpes simplex encephalitis (HSE), a rare, but life threatening consequence of infection 
of the central nervous system (CNS) (62).  Through recurrent infection in adults or 
maternal transmission to neonates, HSV-1 infects the brain and causes acute 
inflammation and significant pathological damage resulting in nearly 70% lethality if 
untreated (26, 62).  In developed countries, HSV remains among the most common 
causes of viral encephalitis(60). 
 
Studies in mouse models and clinical studies have underscored the importance of the 
immune response, especially type I IFN, in protection of the host from encephalitis (11, 
15, 22, 68).  In response to viral infection, type I IFN initiates a signaling cascade to 
stimulate the immune system and provide a first line defense against invading pathogens 
(50).  Consisting of IFNβ and several forms of IFNα, type I IFN binds a receptor 
(IFNAR) to induce an anti-viral state through production of numerous interferon 
stimulated genes (ISGs) (19, 23, 53).  In the absence of type I IFN signaling, mice are 
very susceptible to disseminated peripheral  HSV-1 infection, leading to increased viral 
replication and increased mortality in vivo (28, 30, 45-46) .   
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In the CNS, type I IFN plays a critical role in control of viral infections .  While 
peripheral tissues rely on plasmacytoid dendritic cells (pDCs) as the major IFN producing 
cells, the brain is largely devoid of this cell type (1-2, 54).  Instead, the CNS relies on 
resident cells including neurons to produce and respond to type I IFN (10).  In the 
absence of type I IFN receptors, mice are very susceptible to encephalitis caused by a 
variety of viral pathogens (9, 15, 22).  Mice and humans with defects in type I IFN 
signaling were also found to be more susceptible to HSE than control groups (13). 
Together, these studies signal the importance of IFN signaling following CNS infection.  
Recent studies, however, have focused on the importance of type I IFN induction in 
limiting viral encephalitis.  In particular, inborn disorders of IFN production, as well as 
TLR-3 mutations, render otherwise healthy individuals susceptible to HSE (5, 68).  These 
data suggest that recognition pathways producing type I IFN in the CNS are as important 
as IFN signaling in controlling virally induced encephalitis. 
 
Work on pathogen-associated molecular patterns (PAMPs) has revealed two major 
recognition pathways that lead to type I IFN production (3).  The toll-like receptor (TLR) 
pathways sample the extracellular milieu via receptors on the cell surface and within 
endosomes (12, 18, 35).   In contrast, the RIG-I like receptor (RLR) pathways utilize a 
variety of sensors to recognize nucleic acid PAMPs within the cytosol of infected cells 
(17, 58, 66).  Each pathway utilizes a variety of adaptors and signaling molecules to 
induce type I IFN production (24, 59, 65), yet both pathways converge onto three 
common signaling molecules: IRF-3, IRF-7, and NFκB (52).  Following activation via 
the upstream recognition pathways, these signaling components bind the IFNβ promoter 
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to form the “IFN enhancesome” (67).   The IFNβ initially produced acts upon the IFNαβ 
receptor (IFNAR) in both an autocrine and paracrine manner. This leads to the induction 
of ISGs and the type I IFN cascade. 
 
While NFκB is activated via independent adaptors, IRF-3 and IRF-7 were initially 
thought to be interchangeable (52).  The formation of IRF-3/IRF-7 homodimers or 
heterodimers was necessary for binding specific regions of the IFNβ promoter and 
production of type I IFN (19-20). Examination of cells and animals deficient in IRF-3 or 
IRF-7, however, revealed distinct roles for the two signaling components.  In the absence 
of IRF-3, mice challenged with HSV-1 showed reduced serum IFNβ production, but 
constant IFNα levels and the mice survived intravenous challenge (21).   In contrast, IRF-
7 deficiency resulted in reduced serum IFNα levels and a corresponding increase in 
mortality following HSV-1 intravenous infection.  Therefore, IRF-7 was believed to 
compensate for the loss of IRF-3 and dubbed “the master regulator” of type I IFN 
dependent immune responses (21).  Some recent studies, however, have indicated that the 
respective impacts of IRF-3 and IRF-7 on HSV-1 replication may not be so clear cut.  For 
example, replication of HSV-1 in IRF-3- or IRF-7-deficient mouse fibroblasts was 
unaffected relative to wild-type cells (21).  One potential explanation postulated in 
several studies is that IRF-3 is specifically targeted by the virus to prevent induction of 
the immune response.  For example, in the absence of viral gene expression, UV-
inactivated HSV-1 induces IRF-3 activation and IFN induction to a greater extent than 
live virus (7, 29, 44). Viral genes including ICP0, virion host shutoff protein, ICP34.5, 
and ICP27 have all been implicated in directly or indirectly targeting IRF-3 (14, 29, 37-
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39, 42-43, 56, 61).  Together, these data suggest that the virus targets IRF-3 and implies 
that IRF-3 can impact HSV-1 infection.   
 
Recent studies from this laboratory demonstrated a significant increase in viral 
replication in immune cells in the absence of IRF-3 (40).  The loss of IRF-3 resulted in 
increased viral replication in bone marrow-derived dendritic cells and macrophages due 
to delayed and deficient type I IFN production.  In the current study, the role of IRF-3 in 
vivo was examined. Utilizing two routes of infection, via the cornea and through direct 
intracranial inoculation, several aspects of HSV-1 infection were evaluated, including 
viral replication, viral tropism, lethality, and cytokine production.  The study confirmed 
previous results showing no significant impact of IRF-3 on replication in peripheral 
tissues (21).  In contrast to previous studies, loss of IRF-3 had a significant impact on 
viral replication, lethality, and cytokine production in the brain following both cornea and 
intracranial routes of infection.  Together, the results demonstrate that IRF-3 is a pivotal 
determinant of viral tropism and determines the outcome of HSV infection of the central 
nervous system.   
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MATERIALS AND METHODS 
Cells, virus, and mice. Vero cells were used for production and determination of viral 
stock titers as previously described (49).  The HSV-1 wild-type strains were strain 17 
(HSV-1 17) and strain McKrae (HSV-1 McKrae) (36, 48).   Mock-treated animals were 
inoculated with uninfected Vero cell lysates prepared in parallel to viral stocks.  The 
mouse strains used were control C57B6 as WT mice and C57B6 IRF-3 deficient mice 
(IRF-3-/-) (52) of either gender.   Mice were housed in the Washington University School 
of Medicine barrier facility and infected in the Washington University School of 
Medicine biohazard facility.  Mice were infected at between 6 and 8 weeks of age.  Mice 
were euthanized, if necessary, in accordance with Federal and University policies. 
 
Animal infection procedures. For corneal infection, mice were anesthetized 
intraperitoneally with ketamine (87mg/kg of body weight) and xylazine (13 mg/kg).  
Corneas were bilaterally scarified with a 25G syringe needle, and virus was inoculated by 
adding 2x106 PFU HSV-1 in a volume of 5µl.  Mice were sacrificed at specified times 
post infection for tissue harvest or observed daily for 21 days to evaluate survival.   
For intracranial infections, mice were anesthetized as described above, and injected 
intracranially with 100 PFU, 1x105 PFU of HSV 17 or mock in a volume of 20µl DMEM 
using a Hamilton syringe with a 26G needle.  Mice were sacrificed at specific times post 
infection for tissue harvest or observed until day 21 post infection to evaluate survival. 
 
Tissue titers.  Following in vivo cornea infection, the following tissues were harvested 
and tittered as previously described (49): corneal swabs, periocular skin, trigeminal 
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ganglia, brain and brain stem.  Briefly, tissues were harvested and stored at -80C until 
processing.  Tissues were mechanically disrupted, sonicated and tittered via standard 
plaque assay on Vero cells.   
 
Histological analysis.  WT and IRF-3-/- mice were infected and harvested at day 3 and 5 
post infection as described above.  Briefly, mice were sacrificed and whole brains were 
harvested into 4 ml of 10% formalin solution for fixation. The brains were then sectioned 
sagittally and every tenth section stained using an anti-HSV-1 polyclonal antibody.  Each 
section was divided into five regions (olfactory bulb, central brain, mid-brain cerebellum, 
and brain stem), and scored as either positive or negative for HSV antigen staining in a 
masked fashion.  Total positive regions were then divided by total sections counted to 
obtain percent antigen positive regions. 
 
Bead based cytokine analysis. Brains and brain stems were isolated and assayed 
following in infection in vivo. A single brain or brain stem was harvested from mice and 
mechanically disrupted in 1ml of phosphate buffered saline (PBS).  Samples were then 
sonicated on ice twice for 30 seconds and centrifuged for 4 minutes at 1500rpm at 4°C.  
Supernatants were transferred to a 1.5mL eppendorf tube and centrifuged for 5 minutes at 
7500rpm at 4°C.  Supernatants were then transferred to new tube and diluted 1:1 with 
serum sample diluent (Bioplex Mouse Serum Sample Kit, Bio-Rad, Hercules, CA).  The 
samples were then stored at -80°C until assayed.  The Bio-Plex assay (Bio-Rad) was 
preformed as described in the kit protocol.  Briefly, equivalent amounts of protein, as 
measured by Bradford assay, were added to each well of a multiplex mouse cytokine Bio-
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Plex array. Cytokine concentrations were determined by comparison to a standard curve 
provided by Bio-Rad and the results are reported as pg/ml/µg protein. The results shown 
are the average from two experiments, with each experiment containing three or more 
mice per data point.  
 
IFN ELISA.  Following a high-dose intracranial infection, brains were harvested  at 12, 
18, and 48 hours post infection.  The brains were mechanically disrupted and sonicated 
two times in 1ml PBS.  Brain samples were then spun at 1.5K in a tabletop centrifuge.  
The supernatant were then harvested and spun at 7.5K in a mini-centrifuge for 10 
minutes.  The clarified supernatants were harvested and stored at -80°C until processing 
by ELISA.  For both IFNβ and IFNα ELISA, 100µl of samples were assayed per kit 
protocol (PBL InterferonSource, Piscataway, NJ). Protein levels were normalized via 
Bradford assay and results were expressed pg IFN per mL per µg protein. 
 
Real time RT-PCR of brain tissue.  At the indicated time post-infection, brains were 
harvested into 2mL of Solution D (4 M guanidine thiocyanate, 25 mL of sodium citrate, 
0.5% sarcosyl, 0.1 M 2-mercaptoethanol) (6) and stored at -80oC.  Total RNA was 
harvested as previously described (45) and resuspended in a small volume of nuclease-
free water.  cDNA was generated using the iScript cDNA synthesis kit as per kit protocol 
(Bio-Rad, Hercules, CA).  PCR reactions were prepared with iQ SYBR green supermix 
(Bio-Rad), 5% acetamide, primers (IDT, Coralville, IA) and 2 L cDNA.  Each PCR 
was performed in duplicate, and each infection condition was replicated in at least 4 mice 
from 3 independent experiments.  Actin primer sequences F-
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5’:TGGTACGACCAGAGGCATACAG; R-5’:CCAACTGGGACGACATGGAG.  IFN-
 primer sequences: F-5’:CAGCTCCAAGAAAGGACGAAC; R-5’: 
GGCAGTGTAACTCTTCTGCAT. 
 
Statistics.  Statistical calculations were determined by Student’s t test and are relative to 
WT control group unless otherwise stated herein.  Statistical analysis of survival curves 
utilized the log-rank test. 
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RESULTS 
IRF-3-/- mice have no defect in controlling HSV-1 infection following peripheral 
cornea infection.  Following infection with 2x106 PFU HSV-1 strain 17, examination of 
corneal eye  swabs from IRF-3-/- and WT mice demonstrated no significant increase in 
viral replication following infection (Figure 3.1A.)  Similarly, periocular skin from IRF-
3-/- mice had no major change in HSV-1 titers compared to control (Figure 3.1B); these 
data suggest that IRF-3 plays only a minor role in HSV-1 control in the epithelial cells of 
the cornea and periocular skin.  Examination of the trigeminal ganglia also demonstrated 
no significant increase in viral replication IRF-3-/- mice  (Figure 3.1C).  Additionally, no 
change was observed in terms of lethality between IRF-3-/- and control; however, 
previous reports have found HSV-1 17 to be less virulent in the C57B6 strain of mice and 
no mice died in the experiments preformed here (33).  Reactivation was also shown to be 
similar between WT and IRF-3-/- suggesting that IRF-3 deficiency had minimal impact 
one HSV-1 latency (Figure 3.2).  Together, the data supported the previous findings by 
Honda et al. and suggest that IRF-3 mediated pathways play only a minor role in 
controlling HSV-1 during peripheral infection (21).    
 
IRF-3-/- mice show increased mortality following cornea infection and an associated 
increase in viral replication in the brain stem.  As mentioned previously, HSV-1 strain 
17 has minimal lethality and neuroinvasiveness in C57B6 mice following peripheral 
challenge (33).  To evaluate lethality and viral replication in the brain, a neurovirulent 
and neuroinvasiveness strain of virus, HSV-1 McKrae, was utilized to determine 
differences between WT and IRF-3-/- mice.  As reported with HSV-1 strain 17, no change 
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in viral titers was observed following HSV-1 McKrae infection in the cornea, the 
periocular skin, or the trigeminal ganglia (Fig 3.3A-B, data not shown).  However, 
infection with the neurovirulent virus resulted in approximately 50% survival in wild-
type mice and less than 10% survival in IRF3-/- mice, demonstrating significantly 
(p<0.05) increased susceptibility of IRF3-/- mice (Fig. 3.4A).  Evaluating viral titers, IRF-
3-/- brain stems were found to have a statistically significant increase in viral replication 
as compared to wild-type controls following corneal challenge (Fig. 3.4B).   Although the 
differences were not statistically significant, whole brain titers from IRF-3-/- mice were 
also increased compared to control (Fig. 3.4C).  Together, these data suggest that IRF-3-/- 
mice have a deficit in their ability to control lethal brain infection. 
 
Loss of IRF-3 results in increased viral replication and increased mortality 
following intracranial HSV-1 infection. The cornea model of HSV-1 infection mimics 
the physiological course of eye disease seen in humans and permits evaluation of viral 
replication in peripheral tissues.  However, many factors can affect the ability of the virus 
to replicate in peripheral tissues and also affect its ability to enter the brain and replicate 
therein.  Therefore, to evaluate the role of IRF-3 on HSV replication in the brain directly, 
100 PFU HSV-1 strain 17 was inoculated into the cortex and the mice were evaluated for 
mortality and viral replication.  There was a significant increase in lethality of HSV in the 
IRF-3-/- mice as compared to the controls (Fig 3.5A). While over 60% of the WT mice 
survived IC injection, less than 20% of the IRF-3-/- mice survived the same challenge.  
Correspondingly, beginning at day 3 and continuing at day 5, IRF-3-/- brains permitted a 
10-100 fold increase in viral replication as compared to control mice (Fig. 3.5B). These 
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results suggest that IRF-3-mediated pathways are important in controlling HSV-1 
replication in brain tissues following direct intracranial injection. 
 
IRF-3-/- mice had increased and altered antigen staining following IC challenge with 
HSV-1.  WT and IRF-3-/- mice were infected intracranially with 100 PFU HSV-1 strain 
17 and harvested at day 3 and 5 post infection.  Sagittal sections of the brain were stained 
with an anti-HSV-1 polyclonal antibody.  Sections were divided into five regions 
(olfactory bulb, central brain, mid-brain cerebellum, and pons/medulla/brain stem), and 
scored as either positive or negative for HSV antigen staining in a masked fashion.  
Following scoring, total antigen positive regions were then divided by total sections 
counted in order to calculate a percentage of antigen-positive regions (Table 1, Fig 3.6-7).  
In general, IRF-3-/- mice displayed a higher percentage of antigen-positive regions than 
WT mice.   The central brain region (cerebral cortex, hippocampus, septum, thalamus, 
and hypothalamus) was the site of inoculation and displayed a consistent and high 
percentage of antigen-positive regions at both day 3 and 5 in both mice (Figure 3.6).  In 
contrast, the mid-brain, cerebellum, and brain stem displayed little antigen staining 
(<10%) in either WT or IRF-3-/- mice at day 3 (Fig. 3.6A).  By day 5, however, IRF-3-/- 
mice displayed a significant increase in antigen positive sections as compared to controls 
in midbrain, cerebellum and brain stem (Fig. 3.6A). In addition to increased antigen 
positive regions, IRF-3-/- mice displayed a distinct antigen staining pattern compared to 
WT mice as shown in representative images from the central brain.   HSV staining of WT 
lesions showed staining foci in cells with neuronal morphology (3.6B). In contrast, IRF-
3-/- brain sections had generalized antigen positive lesions with entire areas appearing 
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uniformly stained with no apparent foci (Fig. 3.6C).   This altered staining was consistent 
in each IRF-3-/- antigen positive region examined and suggest increased antigen 
production and spread in IRF-3-/- brains compared to control (Fig. 3.7).  Together, the 
increase in antigen production and  distribution correlate with the previously observed 
increased viral titers in IRF-3-/- brains (Fig. 3.4 & 3.5).   
 
IRF-3-/- mice produce increased amounts of inflammatory cytokines following direct 
intracranial infection.  In addition to HSV-1 replication, several studies have implicated 
inflammatory cytokines as contributing to increased lethality following CNS infection 
(31-32).  To assess inflammatory cytokine production in IRF-3-/- mice, total brain 
homogenates were prepared and cytokines were assayed by a bead-based multiplex array 
following IC infection with 100 PFU of HSV-1 strain 17 or mock treatment (Fig. 3.8).  In 
both the IRF-3-/- and WT brains, cytokine samples taken on day 3 were showed minimal 
induction of cytokines with little or no variation between the virus-infected or mock-
treated groups.  At day 5, however, there was a significant increase in several 
inflammatory cytokines in infected IRF-3-/- brains as compared to WT infected mice.  
IRF-3-/- brains produced a 3.5 fold increase in IL-1β, a 4.6 fold increase in TNFα, and a 
5.8 fold increase in IL-6 as compared to infected WT brains.  This trend also extended to 
IL-12 (7.1 fold), IL-10 (3.6 fold), as well as several chemokines including MCP-1, 
Rantes, and MIP1β.  In contrast, one cytokine (KC) demonstrated similar levels of 
production in the WT and IRF-3-/-  group. In addition, several were globally upregulated 
(IL-5, IL-13, GM-CSF) in both WT and IRF-3-/- mice following virus- or mock-infection 
suggesting that mechanical damage of injection was sufficient to induce their expression 
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(Fig 3.8, data not shown).  Together, the data suggest that in response to HSV-1 infection, 
IRF-3-/- deficient mice produce a stronger inflammatory response as measured by 
cytokine production.  The timing of this increase in inflammatory cytokines, on day 5, 
also coincided with the lethality seen in this model of infection. 
 
IRF-3-/- mice have increased cytokine expression in the brain stem following 
peripheral infection.  Having shown increased cytokine expression in brains following 
direct intracranial injection, it was of interest to observe changes in cytokine levels 
following peripheral infection. Examination of the brain stem revealed increased 
production for several cytokines in the IRF-3-/- mice as compared to control mice (Fig. 
3.9).   While maintaining similar levels at day 3, several cytokines had increased 
expression at both days 5 and 7 in IRF-3-deficient mice. For example, there was 
increased expression of IL-6, IL-12 and IFNγ at days 5 and 7 post infection.  Other 
cytokines had increased only at day 7 including IL-10, MCP-1, and G-CSF (data not 
shown).   The increased cytokine production at this late time corresponded with the peak 
in lethality seen following corneal infection, consistent with inflammation being a cause 
of increased mortality in IRF-3-/- mice.  
 
IRF-3 deficient mice have a deficiency in type I IFN production.  Previous work 
demonstrated a deficit in the production of IFNβ following infection of IRF-3-/- bone 
marrow-derived dendritic cells as compared to control cells (40). The current experiments 
sought to determine whether IRF-3-deficient mice displayed a similar IFNβ production 
deficit in brain tissues following IC infection. WT and IRF-3-/- mice were challenged with 
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a high dose of HSV-1 and brains were harvested 12 and 18 hours post infection.  At both 
12 and 18 hours post infection there was a statistically significant difference in IFNβ 
protein levels in IRF-3-/- mice as compared to WT control mice (Fig. 3.10A). At 12 hours 
post infection, WT mice produce nearly 3.5 fold more IFNβ compared to IRF-3-/-, and 2.2 
fold more IFNβ at 18 hours post infection.  The 12 and 18 hour results therefore 
recapitulated the results previously reported for BMDCs(40) and are consistent with the 
observation that IRF-3-/- mice permit increased viral replication, and show increased 
susceptibility to infection. 
 
Previous studies in vivo showed no change in serum IFNα levels relative to control mice 
following intravenous infection of IRF-3-/- mice with HSV-1 (21). The authors concluded 
that IRF-7 was primarily responsible for IFNα production in vivo. To further assess that 
idea in this work, brain samples were assayed by ELISA for IFNα (Fig. 3.10B).  The data 
showed a defect in IFNα production in IRF-3-/- mice as compared to WT control mice at 
all time points tested. At 12 hours post infection, WT mice have nearly 5 fold more IFNα 
than IRF-3- deficient brains which remained at minimal levels. However, by 18 hours, 
IFNα production from IRF-3-/- brains was significantly above background levels 
suggesting an IRF-3 independent response to viral challenge, consistent with a role for 
IRF-7. While this IFNα production is still notably deficient compared to WT, it does 
suggests that IRF-3-/- mice are capable of inducing the type I IFN cascade.  Together, the 
results confirm a  deficit and delay in the induction of type I IFN in IRF-3-/- mice in vivo. 
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The previous results demonstrated a significant difference between IRF-3-/- and WT mice 
in terms of type I IFN production.  However, those experiments required a higher dose of 
HSV-1; attempts at a lower dose had failed to detect IFN within the linear range of the 
ELISA assay.  Therefore, following IC infection with 100 PFU of HSV-1, WT and IRF-
3-/- brains were removed, the olfactory bulb and brain stem discarded, and RNA harvested 
from the remaining brain for analysis 18 hours post infection.  The results demonstrated a 
statistically significant decrease in fold expression of IFNβ RNA in IRF-3-/-  mice as 
compared to controls (Fig. 3.10C).  The WT brains averaged a 3.4 fold increase in IFNβ 
transcript as compared to mock samples; while in contrast, IRF-3-/- brains averaged a 1.9 
fold increase. These results, coupled with the type I IFN ELISA results following high 
dose infection, demonstrate a deficiency in type I IFN production in the brains of IRF-3-/- 
mice. 
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Discussion 
The data in this study show that IRF-3 plays a critical role in the control of HSV-1 CNS 
infection.  While no impact of loss of IRF-3 was observed in peripheral tissues, its 
absence significantly delayed and reduced type I IFN production in the brain. Therefore, 
deficient IFN response most likely permitted HSV-1 to establish a foothold for infection, 
resulting in increased viral replication and antigen staining in IRF-3-/- brains.   
Concomitant with increased viral replication, the immune system induced an increased 
inflammatory cytokine response in IRF-3-deficient mice and these factors combined to 
result in significantly increased lethality.  Together, these results highlight the importance 
of the IRF-3 dependent immune response in preventing lethal CNS infection following 
HSV-1 challenge. 
Similar to previous reports in immune cells (40), IRF-3-/- deficient mice had 
reduced type I IFN production in the brain following HSV-1 challenge, and delayed or 
reduced type I IFN production has broad implications for susceptibility to viral 
replication in the CNS.   Deficient type I IFN production in brains contributes to 
encephalitis in a variety of RNA virus infections including West Nile, Semliki virus, and 
mouse hepatitis virus (8-9, 15, 22).  The results also correspond with genetic studies in 
humans demonstrating a deficiency in TLR signaling, specifically TLR-3, whose loss 
results in increased susceptibility to HSE (5, 68).  While TLR3 is dispensable for 
protection of mice from viral infection, IRF-3 is apparently required for protection. IRF-3 
is downstream of TLR-3 in the signaling pathway and these findings emphasize the 
importance of this type I IFN induction pathway in controlling HSE in vivo (59).   
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In addition to controlling viral replication, the inflammatory response to CNS 
infection is also thought to contribute to lethality following HSV-1 challenge.  Indeed, 
the inflammatory response is both protective and harmful to the host during HSE.  
Deletion or inhibition of parts of the inflammatory response result in the host succumbing 
to HSV-1 infection (4, 34, 55).  In contrast, antagonizing other inflammatory elements 
has positive results in terms of morbidity and mortality (31-32, 41).  In the absence of 
type I IFN signaling, several viruses have been reported to induce increased CNS 
inflammation in addition to increased viral replication (22, 57).  A similar pattern 
emerges in these studies, as IRF-3-/- mice have increased inflammatory cytokine 
production in the brains following IC and cornea infection. The increase in inflammatory 
cytokine production in IRF-3-/- mice preceded the major peak in lethality in both models.  
These data suggest that increased inflammatory cytokine production, in addition to 
increased viral replication, result in the increased mortality seen in IRF-3-/- mice. 
 Previous work with other viruses has suggested an alteration in viral distribution 
or viral tropism in the context of defective or antagonized type I IFN signaling (16, 22, 
51).  In this study, assessment of viral antigen distribution revealed that while initially 
limited to the central brain region, HSV-1 was distributed in the brain stem, cerebellum, 
and mid-brain in both WT and IRF-3-/- mice by day 5 following IC infection.  In each 
region, IRF-3-/- brains exhibited a higher percentage of antigen positive regions, but the 
overall location of the virus was similar between the WT and IRF-3-/- mice.  There was, 
however, a distinct antigen staining patterns in IRF-3-/- and WT brain sections.  IRF-3-/- 
mice showed lesions with uniform antigen positive regions while WT lesions showed 
HSV-1 staining foci in cells with neuronal morphology. This observation is consistent 
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with the hypothesis that IRF-3-/-  mice permitting initial uncontrolled viral replication and 
resulting in wide, uniform antigen staining.  
The data presented in this study demonstrate a more complex role for IRF-3 than 
previously shown (21).  There is consistency between the previous study and the current 
data examining replication in corneas, trigeminal ganglia, and periocular skin (data not 
shown), but there are also some sharp distinctions when considering the current 
observation of increased lethality and brain titers.  A possible explanation is the nature of 
the immune response in the CNS.  In peripheral tissues, the type I IFN response is 
primarily driven by plasmacytoid dendritic cells in an IRF-7 dependent manner; high 
levels of IFNα are produced which can compensate for the loss of IRF-3 dependent 
pathways (27).  This model is supported by the previous intravenous challenge data (21) 
and data in this study.   In contrast, CNS tissues require local production of type I IFN to 
control viral infection; serum IFN cannot compensate for an IRF-3 deficiency because 
peripheral type I IFN fails to penetrate the blood brain barrier (10-11).  Therefore, in the 
brains of IRF-3-/- mice, HSV-1 can replicate uninhibited for several hours without 
hindrance from type I IFN.  Eventually, the type I IFN response is triggered through an 
IRF-3 independent pathway, but by this time HSV-1 has established a foothold in the 
CNS.  This facilitates increased viral titers and inflammatory cytokine production in IRF-
3-/- mice and lead to encephalitis and a significant increase in lethality.   
Taken together, these data demonstrate a critical role for IRF-3 in the brain 
following HSV-1 challenge.  The results also demonstrate a major delineation between 
the peripheral and CNS innate immune responses. The data also underscore the 
importance of testing multiple infection models, and measuring multiple parameters to 
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fully ascertain the roles of host resistance factors in viral infection. Ongoing experiments 
in our laboratory seek to evaluate changes in viral tropism and inflammatory infiltrates in 
the brain of IRF-3-/- mice.  Further experiments will determine the precise pathways and 
molecules responsible for HSV-1 recognition.  Several candidates involved in the early 
recognition pathways have been implicated and cells and mice lacking these components 
are being evaluated both in vitro and in vivo. 
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Figure 3.1.  IRF-3-/- mice have no change in peripheral tissues following infection 
with HSV-1 17.    WT and IRF-3-/-  mice were infected with 2x106 pfu HSV-1  17 per 
eye.  (A) Cornea swabs,  (B) periocular skin, and (C) trigeminal ganglia were harvested 
and titered at the specified days.  The graphs represent the average of several mice at 
each time point from two independent experiments. 
 
Figure 3.2. Reactivation is not changed in IRF-3-/- mice as compared to control.  
WT and IRF-3-/-  mice were infected with 2x106 pfu HSV-1  17 per eye. Following 
establishment of a latent infection, defined as 28 days post-infection, mice were 
sacrificed and trigeminal ganglia (TGs) harvested. TGs  were bisected and co-cultured on 
a monolayer of Vero cells. Supernatants were removed daily for 7 days post-explant and 
added to fresh Vero monolayers.  This monolayer was then scored for cytopathic effect 
and the results were recorded as the percentage of wells positive for reactivation.   
 
Figure 3.3.  IRF-3 plays a minimal role in peripheral tissues following corneal 
infection with HSV-1 McKrae.  WT and IRF-3-/-  mice were infected with 2x106 pfu 
HSV-1 McKrae per eye.  (A) Cornea swabs and (B) trigeminal ganglia were harvested 
and titered at the specified days.  The graphs represent the average of several mice at 
each time point from two independent experiments.  
 
Figure 3.4, IRF-3-/- mice have increased lethality and increased viral replication in 
brain tissues following HSV-1 McKrae cornea infection.. (A) Survival plot following 
infection of WT and IRF-3-/- deficient mice with 2x106 pfu HSV-1 McKrae per eye. 
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Survival experiments were conducted independently of the other experiments and 
represent the sum of multiple experiments. (B) Brains and (C) brain stems were harvested 
and titered at the specified days following infection of WT and IRF-3-/- deficient mice 
with 2x106 pfu HSV-1 McKrae per eye. The graphs represent the average of several mice 
from two independent experiments. The dotted line represents the limit of detection for 
this assay.  **p value <0.01.  
 
Figure 3.5. IRF-3-/- mice have reduced survival and increased viral titers in the 
brain following HSV-1 strain 17 intracranial infection..  (A) Survival plot of IRF3-/-  
and WT mice following intracranial infection with 100 pfu HSV-1 17. Survival 
experiments were conducted independent of the other experiments and represents the sum 
of experiments.  (B) Viral titers in whole brain tissue harvested at the specified days. 
Data  represents the average of several mice from two independent experiments. The 
dotted line represents the limit of detection for this assay.  *p value <0.05 **p value 
<0.01.  
 
Figure 3.6.  IRF-3-/- brain sections have increased antigen stain following 
intracranial HSV-1 infection.  Following IC infection with 100 PFU HSV-1 strain 17,  
brains were harvested on day 3 and day 5 post infection, formalin fixed, sectioned 
sagittally, and stained with a polyclonal anti-HSV antibody.  Sections were divided into 
five regions (olfactory bulb, central brain, mid-brain cerebellum, and pons/medulla/brain 
stem), and scored as either positive or negative for HSV antigen staining in a masked 
fashion.  Following scoring, total antigen positive regions were then divided by total 
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sections counted in order to calculate a percentage of antigen-positive regions for day and 
day 5 (A). B and C, representative immunoperoxidase stained (?) images from the central 
brain region of WT and  IRF-3-/-  mice .   *p value <0.05 **p value <0.01   
 
Table 3.1.  Summary of antigen scoring in IRF-3-/- and WT mice following IC 
infection with HSV-1 or mock.   Following IC infection with 100 PFU HSV-1 strain 17 
or mock,  brains were harvested on day 1,  day 3, and day 5 post infection, formalin 
fixed, sectioned sagittally, and stained with a polyclonal anti-HSV antibody.  Sections 
were divided into five regions (olfactory bulb, central brain, mid-brain cerebellum, and 
pons/medulla/brain stem), and scored as either positive or negative for HSV antigen 
staining in a masked fashion.  Following scoring, total antigen positive regions were then 
divided by total sections counted in order to calculate a percentage of antigen-positive 
regions for each day and condition.  
 
Figure 3.7. Representative  brain sections from IRF-3-/- following HSV-1 infection 
demonstrate altered antigen staining compared to control.  Following IC infection 
with 100PFU HSV-1 strain 17, brains were harvested on day 5, formalin fixed, sectioned 
sagittally, and stained with a polyclonal anti-HSV antibody.  Representative 
immunoperoxidase stained images of mock, WT, and IRF-3-/- from the (A) (B) (C) 
regions are shown.  
 
Figure 3.8. IRF-3-/- mice show increased inflammatory cytokine production 
following intracranial infection with HSV-1 strain 17.  Following IC infection with 
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100 PFU HSV-1 17, brains were harvested on days 3 and 5 post infection, processed, and 
assayed via a bead based cytokine assay (BioPlex, Bio-Rad).   The results shown are the 
average 4-6 mice brain stems per group per time point.  Statistical calculations based on 
infected WT and infected IRF-3-/- mice.  *p value <0.05.  
 
Figure 3.9. IRF-3-/- mice show increased inflammatory cytokine production 
following peripheral infection.  Following IC infection with 100 PFU HSV-1 17, brains 
were harvested on days 3 and 5 post infection, processed, and assayed via a bead based 
cytokine assay (BioPlex, Bio-Rad).   The results shown are the average 4-6 mice brain 
stems per group per time point.  *p value <0.05 **p value <0.01***p value<0.001.  
 
Figure 3.10.  IRF-3-/- mice have a deficit in type I IFN production following 
intracranial infection with HSV-1.  WT and IRF-3-/- deficient mice were infected with 
1x106 pfu HSV-1 strain 17.  Whole brain tissue was harvested as specified times, 
processed, and analyzed  for (A) IFNβ and (B) IFNα by ELISA (PBL Laboratories).  
Results shown represent the average of 10-14 mice per group per time point from two 
separate experiments. (C) Following infection with 100pfu HSV-1 strain 17, brain tissue, 
excluding brain stem and olfactory bulb, were harvested for RNA 18 hours post infection.  
Samples were assayed by real-time RT-PCR and are expressed as fold expression over 
mock infected samples.  Results shown are the average fold expression from 6-7 mice per 
group per time point from two separate experiments. *p value <0.05 **p value 
<0.01***p value<0.001.  
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Figure 3.1.  IRF-3-/- mice have no change in peripheral tissues following infection 
with HSV-1 17. 
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Figure 3.2.  Reactivation is not changed in IRF-3-/- mice as compared to control.   
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Figure 3.3. IRF-3 plays a minimal role in peripheral tissues following corneal 
infection with HSV-1 McKrae.   
  
113 
 
Figure 3.4, IRF-3-/- mice have increased lethality and increased viral replication in 
brain tissues following HSV-1 McKrae cornea infection.. 
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Figure 3.5. IRF-3-/- mice have reduced survival and increased viral titers in the 
brain following HSV-1 strain 17 intracranial infection. 
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Figure 3.6.   IRF-3-/- brain sections have increased antigen stain following 
intracranial infection.   
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Table 3.1, Summary of antigen scoring in IRF-3-/- and WT mice following IC 
infection with HSV-1 or mock. 
 
Sample  
 
Olfactory 
Bulb 
Central 
Brain 
Mid-
Brain 
Cerebellum Brain 
Stem 
Number 
of Mice 
IRF-3-/- 
Day 3 2.6% 
(1/39) 
59.1% 
(26/44) 
0% 
(0/42)
7.9% 
(3/38)
8.3% 
(3/36) 
9 
WT 
Day 3 2.9% 
1(35) 
53.5% 
(23/43)
2.3% 
(1/43)
0% 
(0/38)
12.5% 
(5/40) 
8 
IRF-3-/- 
Day 5 2.9% 
(1/34) 
67.3% 
(33/49)
36.2% 
(17/47)
29.8% 
(14/47)
54.2% 
(26/48) 
9 
WT 
Day 5 7.3% 
(2/41) 
53.5% 
(24/45)
15.6% 
(7/45)
4.4% 
(2/45)
33.3% 
(14/42) 
9 
IRF-3-/- 
Mock 0% 
(0/16) 
6.3% 
(1/16)
0% 
(0/16)
0% 
(0/15)
0% 
(0/16) 
4 
WT 
Mock 0% 
(0/9) 
8.3% 
(1/12)
0% 
(0/12)
0% 
(0/12)
0% 
(0/12) 
3 
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Figure 3.7, Representative brain sections from IRF-3-/- following HSV-1 infection 
demonstrate altered antigen staining compared to control.   
 
 
 Brain Stem Cerebellum Central Brain 
 
 
Mock 
 
 
WT 
 
 
IRF-
3-/- 
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Figure 3.8.  IRF-3-/- mice show increased inflammatory cytokine production 
following intracranial infection.   
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Figure 3.9. IRF-3-/- mice show increased inflammatory cytokine production 
following peripheral infection. 
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Figure 3.10.  IRF-3-/- mice have a deficit in type I IFN production following 
intracranial infection with HSV-1.   
  
121 
 
References  
1. Asselin-Paturel, C., A. Boonstra, M. Dalod, I. Durand, N. Yessaad, C. 
Dezutter-Dambuyant, A. Vicari, A. O'Garra, C. Biron, F. Briere, and G. 
Trinchieri. 2001. Mouse type I IFN-producing cells are immature APCs with 
plasmacytoid morphology. Nat Immunol 2:1144-50. 
2. Bjorck, P. 2001. Isolation and characterization of plasmacytoid dendritic cells 
from Flt3 ligand and granulocyte-macrophage colony-stimulating factor-treated 
mice. Blood 98:3520-6. 
3. Bowie, A. G., and L. Unterholzner. 2008. Viral evasion and subversion of 
pattern-recognition receptor signalling. Nat Rev Immunol 8:911-922. 
4. Bradford, Russell D., April C. Pettit, Patty W. Wright, Mark J. Mulligan, 
Larry W. Moreland, David A. McLain, John W. Gnann, and Karen C. 
Bloch. 2009. Herpes Simplex Encephalitis during Treatment with Tumor 
Necrosis Factor–α Inhibitors. Clinical Infectious Diseases 49:924-927. 
5. Casrouge, A., S. Y. Zhang, C. Eidenschenk, E. Jouanguy, A. Puel, K. Yang, 
A. Alcais, C. Picard, N. Mahfoufi, N. Nicolas, L. Lorenzo, S. Plancoulaine, B. 
Senechal, F. Geissmann, K. Tabeta, K. Hoebe, X. Du, R. L. Miller, B. Heron, 
C. Mignot, T. B. de Villemeur, P. Lebon, O. Dulac, F. Rozenberg, B. Beutler, 
M. Tardieu, L. Abel, and J. L. Casanova. 2006. Herpes simplex virus 
encephalitis in human UNC-93B deficiency. Science 314:308-12. 
6. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by 
acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 
162:156-9. 
7. Collins, S. E., R. S. Noyce, and K. L. Mossman. 2004. Innate cellular response 
to virus particle entry requires IRF3 but not virus replication. J Virol 78:1706-17. 
8. Daffis, S., M. A. Samuel, B. C. Keller, M. Gale, and M. S. Diamond. 2007. 
Cell-specific IRF-3 responses protect against West Nile virus infection by 
interferon-dependent and -independent mechanisms. PLoS Pathog 3. 
9. Daffis, S., M. A. Samuel, M. S. Suthar, B. C. Keller, M. Gale, and M. S. 
Diamond. 2008. Interferon regulatory factor IRF-7 induces the antiviral alpha 
interferon response and protects against lethal West Nile virus infection. J Virol 
82:8465-8475. 
10. Delhaye, S., S. Paul, G. Blakqori, M. Minet, F. Weber, P. Staeheli, and T. 
Michiels. 2006. Neurons produce type I interferon during viral encephalitis. Proc 
Natl Acad Sci U S A 103:7835-40. 
122 
 
11. Detje, C. N., T. Meyer, H. Schmidt, D. Kreuz, J. K. Rose, I. Bechmann, M. 
Prinz, and U. Kalinke. 2009. Local type I IFN receptor signaling protects against 
virus spread within the central nervous system. J Immunol 182:2297-304. 
12. Diebold, S. S., T. Kaisho, H. Hemmi, S. Akira, and C. Reis e Sousa. 2004. 
Innate antiviral responses by means of TLR7-mediated recognition of single-
stranded RNA. Science 303:1529-1531. 
13. Dupuis, S., E. Jouanguy, S. Al-Hajjar, C. Fieschi, I. Z. Al-Mohsen, S. Al-
Jumaah, K. Yang, A. Chapgier, C. Eidenschenk, P. Eid, A. Al Ghonaium, H. 
Tufenkeji, H. Frayha, S. Al-Gazlan, H. Al-Rayes, R. D. Schreiber, I. Gresser, 
and J. L. Casanova. 2003. Impaired response to interferon-alpha/beta and lethal 
viral disease in human STAT1 deficiency. Nat Genet 33:388-91. 
14. Eidson, K. M., W. E. Hobbs, B. J. Manning, P. Carlson, and N. A. DeLuca. 
2002. Expression of herpes simplex virus ICP0 inhibits the induction of 
interferon-stimulated genes by viral infection. J Virol 76:2180-91. 
15. Fragkoudis, R., L. Breakwell, C. McKimmie, A. Boyd, G. Barry, A. Kohl, A. 
Merits, and J. K. Fazakerley. 2007. The type I interferon system protects mice 
from Semliki Forest virus by preventing widespread virus dissemination in 
extraneural tissues, but does not mediate the restricted replication of avirulent 
virus in central nervous system neurons. J Gen Virol 88:3373-84. 
16. Gardner, C. L., C. W. Burke, M. Z. Tesfay, P. J. Glass, W. B. Klimstra, and 
K. D. Ryman. 2008. Eastern and Venezuelan Equine Encephalitis Viruses Differ 
in Their Ability To Infect Dendritic Cells and Macrophages: Impact of Altered 
Cell Tropism on Pathogenesis. J. Virol. 82:10634-10646. 
17. Gitlin, L., W. Barchet, S. Gilfillan, M. Cella, B. Beutler, R. A. Flavell, M. S. 
Diamond, and M. Colonna. 2006. Essential role of mda-5 in type I IFN 
responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis 
picornavirus. Proc Natl Acad Sci U S A 103:8459-8464. 
18. Hemmi, H., O. Takeuchi, T. Kawai, T. Kaisho, S. Sato, H. Sanjo, M. 
Matsumoto, K. Hoshino, H. Wagner, K. Takeda, and S. Akira. 2000. A Toll-
like receptor recognizes bacterial DNA. Nature 408:740-745. 
19. Honda, K., A. Takaoka, and T. Taniguchi. 2006. Type I interferon [corrected] 
gene induction by the interferon regulatory factor family of transcription factors. 
Immunity 25:349-60. 
20. Honda, K., and T. Taniguchi. 2006. IRFs: master regulators of signalling by 
Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol 
6:644-58. 
21. Honda, K., H. Yanai, H. Negishi, M. Asagiri, M. Sato, T. Mizutani, N. 
Shimada, Y. Ohba, A. Takaoka, N. Yoshida, and T. Taniguchi. 2005. IRF-7 is 
123 
 
the master regulator of type-I interferon-dependent immune responses. Nature 
434:772-777. 
22. Ireland, D. D., S. A. Stohlman, D. R. Hinton, R. Atkinson, and C. C. 
Bergmann. 2008. Type I interferons are essential in controlling neurotropic 
coronavirus infection irrespective of functional CD8 T cells. J Virol 82:300-10. 
23. Katze, M. G., Y. He, and M. Gale. 2002. Viruses and interferon: a fight for 
supremacy. Nat Rev Immunol 2:675-687. 
24. Kawai, T., K. Takahashi, S. Sato, C. Coban, H. Kumar, H. Kato, K. J. Ishii, 
O. Takeuchi, and S. Akira. 2005. IPS-1, an adaptor triggering RIG-I- and Mda5-
mediated type I interferon induction. Nat Immunol 6:981-988. 
25. Kaye, S., and A. Choudhary. 2006. Herpes simplex keratitis. Prog Retin Eye 
Res 25:355-80. 
26. Kimberlin, D. W., F. D. Lakeman, A. M. Arvin, C. G. Prober, L. Corey, D. A. 
Powell, S. K. Burchett, R. F. Jacobs, S. E. Starr, and R. J. Whitley. 1996. 
Application of the polymerase chain reaction to the diagnosis and management of 
neonatal herpes simplex virus disease. National Institute of Allergy and Infectious 
Diseases Collaborative Antiviral Study Group. J Infect Dis 174:1162-1167. 
27. Lang, P. A., L. Cervantes-Barragan, A. Verschoor, A. A. Navarini, M. 
Recher, M. Pellegrini, L. Flatz, A. Bergthaler, K. Honda, B. Ludewig, P. S. 
Ohashi, and K. S. Lang. 2009. Hematopoietic cell-derived interferon controls 
viral replication and virus-induced disease. Blood 113:1045-52. 
28. Leib, D. A., T. E. Harrison, K. M. Laslo, M. A. Machalek, N. J. Moorman, 
and H. W. Virgin. 1999. Interferons regulate the phenotype of wild-type and 
mutant herpes simplex viruses in vivo. J Exp Med 189:663-672. 
29. Lin, R., R. S. Noyce, S. E. Collins, R. D. Everett, and K. L. Mossman. 2004. 
The herpes simplex virus ICP0 RING finger domain inhibits IRF3- and IRF7-
mediated activation of interferon-stimulated genes. J Virol 78:1675-84. 
30. Luker, G. D., J. L. Prior, J. Song, C. M. Pica, and D. A. Leib. 2003. 
Bioluminescence imaging reveals systemic dissemination of herpes simplex virus 
type 1 in the absence of interferon receptors. J Virol 77:11082-93. 
31. Lundberg, P., H. Openshaw, M. Wang, H. J. Yang, and E. Cantin. 2007. 
Effects of CXCR3 signaling on development of fatal encephalitis and corneal and 
periocular skin disease in HSV-infected mice are mouse-strain dependent. Invest 
Ophthalmol Vis Sci 48:4162-70. 
32. Lundberg, P., C. Ramakrishna, J. Brown, J. M. Tyszka, M. Hamamura, D. 
R. Hinton, S. Kovats, O. Nalcioglu, K. Weinberg, H. Openshaw, and E. M. 
Cantin. 2008. The immune response to herpes simplex virus type 1 infection in 
124 
 
susceptible mice is a major cause of central nervous system pathology resulting in 
fatal encephalitis. J Virol 82:7078-88. 
33. Lundberg, P., P. Welander, H. Openshaw, C. Nalbandian, C. Edwards, L. 
Moldawer, and E. Cantin. 2003. A locus on mouse chromosome 6 that 
determines resistance to herpes simplex virus also influences reactivation, while 
an unlinked locus augments resistance of female mice. J Virol 77:11661-73. 
34. Lundberg, P., P. V. Welander, C. K. Edwards, 3rd, N. van Rooijen, and E. 
Cantin. 2007. Tumor necrosis factor (TNF) protects resistant C57BL/6 mice 
against herpes simplex virus-induced encephalitis independently of signaling via 
TNF receptor 1 or 2. J Virol 81:1451-60. 
35. Matsumoto, M., S. Kikkawa, M. Kohase, K. Miyake, and T. Seya. 2002. 
Establishment of a monoclonal antibody against human Toll-like receptor 3 that 
blocks double-stranded RNA-mediated signaling. Biochem Biophys Res Commun 
293:1364-1369. 
36. McGeoch, D. J., M. A. Dalrymple, A. J. Davison, A. Dolan, M. C. Frame, D. 
McNab, L. J. Perry, J. E. Scott, and P. Taylor. 1988. The complete DNA 
sequence of the long unique region in the genome of herpes simplex virus type 1. 
J Gen Virol 69 ( Pt 7):1531-74. 
37. Melchjorsen, J., J. Siren, I. Julkunen, S. R. Paludan, and S. Matikainen. 
2006. Induction of cytokine expression by herpes simplex virus in human 
monocyte-derived macrophages and dendritic cells is dependent on virus 
replication and is counteracted by ICP27 targeting NF-kappaB and IRF-3. J Gen 
Virol 87:1099-1108. 
38. Melroe, G. T., N. A. DeLuca, and D. M. Knipe. 2004. Herpes simplex virus 1 
has multiple mechanisms for blocking virus-induced interferon production. J 
Virol 78:8411-20. 
39. Melroe, G. T., L. Silva, P. A. Schaffer, and D. M. Knipe. 2007. Recruitment of 
activated IRF-3 and CBP/p300 to herpes simplex virus ICP0 nuclear foci: 
Potential role in blocking IFN-beta induction. Virology 360:305-321. 
40. Menachery, V. D., and D. A. Leib. 2009. Control of herpes simplex virus 
replication is mediated through an interferon regulatory factor 3-dependent 
pathway. J Virol 83:12399-406. 
41. Milatovic, D., Y. Zhang, S. J. Olson, K. S. Montine, L. J. Roberts, 2nd, J. D. 
Morrow, T. J. Montine, T. S. Dermody, and T. Valyi-Nagy. 2002. Herpes 
simplex virus type 1 encephalitis is associated with elevated levels of F2-
isoprostanes and F4-neuroprostanes. J Neurovirol 8:295-305. 
42. Mossman, K. L., H. A. Saffran, and J. R. Smiley. 2000. Herpes simplex virus 
ICP0 mutants are hypersensitive to interferon. J Virol 74:2052-6. 
125 
 
43. Mossman, K. L., and J. R. Smiley. 2002. Herpes simplex virus ICP0 and 
ICP34.5 counteract distinct interferon-induced barriers to virus replication. J Virol 
76:1995-8. 
44. Paladino, P., D. T. Cummings, R. S. Noyce, and K. L. Mossman. 2006. The 
IFN-independent response to virus particle entry provides a first line of antiviral 
defense that is independent of TLRs and retinoic acid-inducible gene I. J Immunol 
177:8008-16. 
45. Pasieka, T. J., B. Lu, S. D. Crosby, K. M. Wylie, L. A. Morrison, D. E. 
Alexander, V. D. Menachery, and D. A. Leib. 2008. Herpes simplex virus 
virion host shutoff attenuates establishment of the antiviral state. J Virol 82:5527-
5535. 
46. Pasieka, T. J., B. Lu, and D. A. Leib. 2008. Enhanced pathogenesis of an 
attenuated herpes simplex virus for mice lacking Stat1. J Virol 82:6052-5. 
47. Pepose, J. S., T. L. Keadle, and L. A. Morrison. 2006. Ocular herpes simplex: 
changing epidemiology, emerging disease patterns, and the potential of vaccine 
prevention and therapy. Am J Ophthalmol 141:547-557. 
48. Perng, G.-C., K. R. Mott, N. Osorio, A. Yukht, S. Salina, Q.-H. Nguyen, A. B. 
Nesburn, and S. L. Wechsler. 2002. Herpes simplex virus type 1 mutants 
containing the KOS strain ICP34.5 gene in place of the McKrae ICP34.5 gene 
have McKrae-like spontaneous reactivation but non-McKrae-like virulence. J Gen 
Virol 83:2933-2942. 
49. Rader, K. A., C. E. Ackland-Berglund, J. K. Miller, J. S. Pepose, and D. A. 
Leib. 1993. In vivo characterization of site-directed mutations in the promoter of 
the herpes simplex virus type 1 latency-associated transcripts. J Gen Virol 74 ( Pt 
9):1859-1869. 
50. Samuel, C. E. 2001. Antiviral actions of interferons. Clin Microbiol Rev 14:778-
809, table of contents. 
51. Samuel, M. A., and M. S. Diamond. 2005. Alpha/Beta Interferon Protects 
against Lethal West Nile Virus Infection by Restricting Cellular Tropism and 
Enhancing Neuronal Survival. J. Virol. 79:13350-13361. 
52. Sato, M., H. Suemori, N. Hata, M. Asagiri, K. Ogasawara, K. Nakao, T. 
Nakaya, M. Katsuki, S. Noguchi, N. Tanaka, and T. Taniguchi. 2000. Distinct 
and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses 
for IFN-alpha/beta gene induction. Immunity 13:539-548. 
53. Sen, G. C. 2001. Viruses and interferons. Annu Rev Microbiol 55:255-81. 
54. Serafini, B., S. Columba-Cabezas, F. Di Rosa, and F. Aloisi. 2000. 
Intracerebral recruitment and maturation of dendritic cells in the onset and 
126 
 
progression of experimental autoimmune encephalomyelitis. Am J Pathol 
157:1991-2002. 
55. Sergerie, Y., S. Rivest, and G. Boivin. 2007. Tumor necrosis factor-alpha and 
interleukin-1 beta play a critical role in the resistance against lethal herpes 
simplex virus encephalitis. J Infect Dis 196:853-60. 
56. Sobol, P. T., and K. L. Mossman. 2006. ICP0 prevents RNase L-independent 
rRNA cleavage in herpes simplex virus type 1-infected cells. J Virol 80:218-25. 
57. Suthar, M. S., D. Y. Ma, S. Thomas, J. M. Lund, N. Zhang, S. Daffis, A. Y. 
Rudensky, M. J. Bevan, E. A. Clark, M.-K. Kaja, M. S. Diamond, and M. 
Gale, Jr. 2010. IPS-1 Is Essential for the Control of West Nile Virus Infection 
and Immunity. PLoS Pathog 6:e1000757. 
58. Takaoka, A., Z. Wang, M. K. Choi, H. Yanai, H. Negishi, T. Ban, Y. Lu, M. 
Miyagishi, T. Kodama, K. Honda, Y. Ohba, and T. Taniguchi. 2007. DAI 
(DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune 
response. Nature 448:501-505. 
59. Takeuchi, O., and S. Akira. 2002. MyD88 as a bottle neck in Toll/IL-1 
signaling. Curr Top Microbiol Immunol 270:155-167. 
60. Tyler, K. L. 2004. Herpes simplex virus infections of the central nervous system: 
encephalitis and meningitis, including Mollaret's. Herpes 11 Suppl 2:57A-64A. 
61. Verpooten, D., Y. Ma, S. Hou, Z. Yan, and B. He. 2009. Control of TANK-
binding kinase 1-mediated signaling by the gamma(1)34.5 protein of herpes 
simplex virus 1. J Biol Chem 284:1097-105. 
62. Whitley, R. J. 2006. Herpes simplex encephalitis: adolescents and adults. 
Antiviral Res 71:141-8. 
63. Whitley, R. J. (ed.). 1996. Herpes Simplex Viruses. Lippencott-Raven 
Publishers, Philadelphia, PA. 
64. Xu, F., M. R. Sternberg, B. J. Kottiri, G. M. McQuillan, F. K. Lee, A. J. 
Nahmias, S. M. Berman, and L. E. Markowitz. 2006. Trends in herpes simplex 
virus type 1 and type 2 seroprevalence in the United States. JAMA 296:964-973. 
65. Yamamoto, M., S. Sato, K. Mori, K. Hoshino, O. Takeuchi, K. Takeda, and 
S. Akira. 2002. Cutting edge: a novel Toll/IL-1 receptor domain-containing 
adapter that preferentially activates the IFN-beta promoter in the Toll-like 
receptor signaling. J Immunol 169:6668-6672. 
66. Yoneyama, M., M. Kikuchi, T. Natsukawa, N. Shinobu, T. Imaizumi, M. 
Miyagishi, K. Taira, S. Akira, and T. Fujita. 2004. The RNA helicase RIG-I 
127 
 
has an essential function in double-stranded RNA-induced innate antiviral 
responses. Nat Immunol 5:730-737. 
67. Yoneyama, M., W. Suhara, Y. Fukuhara, M. Fukuda, E. Nishida, and T. 
Fujita. 1998. Direct triggering of the type I interferon system by virus infection: 
activation of a transcription factor complex containing IRF-3 and CBP/p300. 
EMBO J 17:1087-95. 
68. Zhang, S.-Y., E. Jouanguy, S. Ugolini, A. Smahi, G. Elain, P. Romero, D. 
Segal, V. Sancho-Shimizu, L. Lorenzo, A. Puel, C. Picard, A. Chapgier, S. 
Plancoulaine, M. Titeux, C. Cognet, H. von Bernuth, C.-L. Ku, A. Casrouge, 
X.-X. Zhang, L. Barreiro, J. Leonard, C. Hamilton, P. Lebon, B. Heron, L. 
Vallee, L. Quintana-Murci, A. Hovnanian, F. Rozenberg, E. Vivier, F. 
Geissmann, M. Tardieu, L. Abel, and J.-L. Casanova. 2007. TLR3 deficiency 
in patients with herpes simplex encephalitis. Science 317:1522-1527. 
 
 
  
128 
 
 
 
 
 
 
 
 
Chapter IV 
Summary, Implications, and Future Directions 
 
  
129 
 
Summary of Research and Goals 
The major goal of this research was to address the role of interferon regulatory 
factor-3 (IRF-3) on herpes simplex virus type 1 (HSV-1) infection both in vitro and in 
vivo.  Prior to these studies, examination of IRF-3 in the context of HSV-1 infection had 
led to contradictory results.  Several studies argued that IRF-3 dependent pathways had 
minimal impact on HSV-1 infection in vitro or in vivo (5, 14).  In contrast, other studies 
demonstrated that HSV-1encodes viral proteins that both directly and indirectly target 
IRF-3 activity, implying a role for IRF-3 in the immune response to HSV-1 (12, 17, 23-
26, 31, 33).  Therefore, the studies in this thesis sought to address the contradiction in 
these data and clarify a role for IRF-3 in the control of HSV-1 infection.  
While numerous studies have implicated the type I IFN response in control of 
virus infection, the data presented here advocates a critical role for IRF-3 and the early 
recognition pathways in initiating control of HSV-1 in vitro and in vivo.  In the absence 
of IRF-3, immune cells in vitro and brain tissues in vivo demonstrated a deficit in type I 
IFN production following HSV-1 challenge.   In each case, the IRF-3-/- cells and animals 
eventually produced a type I IFN response; however, the delay and reduction in type I 
IFN early during infection permitted an immediate increase in HSV-1 replication.  Over 
the course of infection, the small change in IFN production early during infection 
manifested in enhanced viral replication leading to an increase in cytokine production.  
These factors led to greater lethality for IRF-3-/- mice in vivo; therefore, the absence of 
IRF-3 resulted in a significant shift in susceptibility.   
However, contrasting major type I IFN cascade knockouts like STAT-1-/- and 
IFNαγR-/-,  IRF-3 deficiency resulted in no temporal shift in the survival curve, but only a 
shift in total  susceptibility.  WT and IRF-3-/- mice died with the same kinetics after both 
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ocular or intracranial HSV-1 infection; the major delineation was the total percentage of 
dead.  The data suggest that the loss of IRF-3 simply increased immediate HSV-1 
replication creating an infectious dose that mimics a higher viral inoculation.  The result 
was increased lethality in IRF-3-/- mice, but in both mice, the likely mechanisms causing 
death were a combination of viral replication and subsequent inflammation in the CNS.  
While the loss of IRF-3 does not ablate a type I IFN response, the delay in induction 
results in an early increase in HSV-1 replication which has major impact on the course 
and outcome of infection.  Overall, the loss of IRF-3 demonstrates the importance of the 
early recognition pathways on a timely immune response to viral challenge. 
From in vitro studies, the necessity of IRF-3 appears to be cell-type dependent.  In 
MEFs, the loss of IRF-3 has minimal impact on HSV-1 replication (14).  In contrast, 
bone marrow derived dendritic cells and macrophages yield increased HSV-1 titers in the 
absence of IRF-3.  One explanation implicates the differing responses to virus infection 
in these cell types.  Immune cells like BMDCs and BMM are expected to have a vigorous 
immune response to viral challenge, producing and responding to type I IFN production.  
In contrast, while MEFs respond to type I IFN stimulation, the cells are unable to 
completely control HSV-1 replication even with IFN pretreatment.  In addition, loss of 
critical components of the IFN response including STAT-1 or IFNαR has only modest 
impact on HSV-1 replication in MEFs.  These data suggest that either an insufficient 
immune response, HSV-1 antagonism, or a combination of both result in reduced efficacy 
of type I IFN in MEFs.  In immune cells, the opposite may be true with a sufficient 
immune response resulting in less effective HSV-1 antagonism.  The loss of IRF-3 in this 
situation results in increased HSV-1 replication in these cell types. Together, the data 
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demonstrate the importance of cell type selection to in vitro experiments.  While MEFs 
represent a standard cell type, their use in examination of the immune system may be 
inadequate.  At a minimum, immune cells like BMDCs and BMM should be used in 
addition to MEFs in characterization of immune functions. 
 In vivo, the necessity of IRF-3 appeared to be CNS specific.  Loss of IRF-3 in 
peripheral tissues has minimal impact on viral replication following  HSV-1 challenge.  
However, in the brain,  IRF-3 deficiency resulted in enhanced viral replication and 
greater inflammatory cytokine titers which likely account for increased lethality seen in 
IRF-3-/- mice.  Examination of type I IFN production revealed a deficit in IRF-3-/- brains 
as compared to controls, providing a mechanism for increased HSV-1 replication and 
suggesting a CNS specific necessity for IRF-3.  While peripheral tissues primarily utilize 
type I IFN production by plasmacytoid dendritic cells (pDCs), the brain is largely devoid 
of this cell type (1-2, 30).  Instead, the CNS relies on resident cells to produce and 
respond to type I IFN (9).  In the absence of IRF-3, the CNS fails to produce an 
immediate type I IFN response and HSV-1 establishes a foothold for infection. 
Augmented viral replication follows which leads to increased cytokine production and 
increased lethality.  In the periphery, the loss of IRF-3 impacts local production of type I 
IFN as demonstrated by reduced IFNβ (14, 29).  However, infiltration by immune cells 
and IRF-7 mediated production of  IFNα likely rescues the type I IFN cascade and 
prevents the virus from establishing a foothold in peripheral tissues.  This exogenous IFN 
production by infiltrating cells is not available in the CNS as few pDCs are found in the 
brain and type I IFN has not been shown to pass through the blood brain barrier (9-10).  
Therefore, the CNS requires local production of type I IFN and IRF-3 is critical for a 
132 
 
timely and efficient response.  In the absence of IRF-3, the virus gains its foothold and 
the result is increased susceptibility to HSV-1 CNS infection. 
 
Implication of Thesis 
Several studies have demonstrated the importance of type I IFN in limiting viral 
infection in the periphery and the CNS.  In the absence of IFNα/γR or IFN signaling, 
mice become very susceptible to infection caused by a variety of viruses including HSV-
1 (6, 8, 13, 15-16, 19).  In this study, the loss of IRF-3 also renders mice more susceptible 
to HSV-1 infection and lethality, but only in the context of CNS infection.  The results 
contrast reports from West Nile virus (WNV) infection of IRF-3-/- mice.  Deficiency in 
IRF-3 results in increased WNV replication in peripheral tissues, altered tissue tropism, 
and earlier entry into the CNS (6).  This data demonstrate that in the context of WNV 
infection, IRF-3 is an essential regulator in both peripheral and CNS tissues.  However, 
the loss of IRF-3 has no detectable impact on HSV-1 replication in the periphery.  
One possible explanation is increased sensitivity of HSV-1 to type I IFN as 
compared to WNV.  In the periphery, the loss of IRF-3-/- has been shown to delay, but not 
significantly diminish systemic accumulation of type I IFN in response to WNV or HSV-
1 infection (6, 14).  The delay in type I production potentially permits a small, immediate 
increase in viral replication in both virus types.  However, the eventual type I IFN 
response in the periphery serves to limit HSV-1 infection and spread.  In contrast, WNV 
is relatively resistant to type I IFN and capitalizes on the initial delay with increased viral 
replication.  Another possible explanation involves cell-type tropism;  WNV infects a 
wider range of cells during its normal course of infection and thus requires the ability to 
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modulate the immune response in a variety of cell types.  In contrast, HSV-1 primarily 
infects epithelial cells and neuronal cell types during physiologically infections; it 
bypasses the need to infect and control immune cells by transport via neuronal axons. 
Therefore, HSV-1 may not have developed methods to antagonize the immune response 
in these cell types.   
Immune cells, including BMDCs and BMM, require IRF-3 dependent pathways 
to limit HSV-1 replication.  In the absence of IRF-3, both BMDCs and BMMs are unable 
to control HSV-1 replication until type I IFN is produced via an alternate pathway.  This 
results in control of HSV-1 infection once the type I IFN response is initiated in the 
periphery in vivo.   This hypothesis is supported by studies of STAT-1-/- and IFNαβγR-/- 
mice.  Loss of type I and type II IFN receptors results in multi-organ failure and systemic 
infection following HSV-1 challenge (19).  In contrast, STAT-1-/- mice control peripheral 
viral replication, but succumb to CNS infection following HSV-1 infection.  A major 
distinction between these mice was the ability to produce and respond to type I IFN via 
the type I IFN receptor (unpublished, Pasieka et al). Antibody blockade of IFNαR 
resulted in systemic infection and organ failure in STAT-1-/- mice.  Together, the data 
from the IRF-3-/- and STAT-1-/- mice demonstrate that systemic HSV-1 infection is 
severely limited by even an attenuated type I IFN response in the periphery.   
In contrast to the periphery, the data demonstrates that IRF-3 dependent pathways 
are critical in limiting viral replication and lethality following infection of the CNS.  In 
both HSV-1 and WNV, the loss of IRF-3 results in increased HSV-1 replication in the 
CNS tissues following direct and peripheral infection (6).  These data correlate with 
observations in humans regarding the role of TLR pathways in herpes simplex 
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encephalitis (HSE).  Inborn disorders of type I IFN production have been demonstrated to 
render healthy individuals susceptible to HSE, most notably mutation in TLR-3 (3, 35).  
In addition, TLR-3 deficiency resulted in enhanced WNV replication in neurons in vitro; 
in vivo, TLR-3-/- mice have greater WNV replication in the CNS and increased lethality 
(7).    While TLR3 is dispensable for protection from HSV-1 infection in mice (35), the 
loss of its downstream signaling molecule, IRF-3, rendered mice susceptible to CNS 
infection in the current study.  Together, these data demonstrate the importance of early 
recognition sensors and IRF-3 dependent pathways in the control of viral infection of the 
CNS.  By initiating a timely type I IFN response,  IRF-3 dependent pathways limit initial 
CNS viral replication; in their absence, viruses like HSV-1 can establish a more robust 
CNS infection that can lead to death.  Therefore, studies examining modulation and 
disruption of the IRF-3 dependent pathways must continue.  Recent work utilizing high 
throughput screening of a pharmacologically active compound library has revealed 
several antipsychotic drugs to be direct inhibitors of innate signaling pathways (36).  
Patients receiving these drugs might be more susceptible to HSE, similar to what has 
been reported in genetic studies for TLR-3 deficiency.   
The results from HSV-1 and WNV infection also suggest a neuroprotective role 
for IRF-3 either through induction of type I IFN or an IRF-3 dependent cascade.   A 
recent study demonstrated that viral infection is not a requirement for protection provided 
by IRF-3 in the brain. Preconditioning of the mouse brain with lipopolysaccharide (LPS) 
protected the mouse from ischemic injury following cerebral artery occlusion; this 
protection was found to be dependent on type I IFN production via IRF-3 dependent 
pathways (22).  Together, the data suggest that IRF-3 may be a suitable therapeutic target 
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for IFN induction in the brain.  Direct treatment within type I IFN has been utilized in a 
variety of human illnesses including hepatitis virus infection, multiple sclerosis and 
gliomas (4, 11, 32).  However, several major problems have been identified in utilizing 
IFN treatment, most notably a short half life in vivo and inaccessibility to the CNS (27).  
In addition,  IFN treatment has been associated with numerous clinical side effects 
including depression and brain toxicity (27) .  By targeting IRF-3 in the brain, treatment 
may lead to physiological appropriate amounts of IFN being produced in the CNS by 
local cells; the result may be increased half-life for IFN in targeted tissues, lowered 
toxicity, and decreased side effects.   Targeting IRF-3 might also be used as a 
prophylactic treatment to prevent viral encephalitis if a person is known to be infected 
with or exposed to HSV-1 or another neurotropic virus.  Whereas a delay in type I IFN 
induction result in augmented viral replication  the CNS,  early induction and priming via 
IRF-3  might limit infection.  A recent study has identified a chemotherapeutic agent, 5,6-
dimethyl-xanthenone-4-acetic acid (DMXAA), as a potent and specific activator of IRF-3 
(28).  Through a yet undetermined mechanism, DMXAA activates IRF-3 pathways in an 
IPS-1 and MYD88 independent manner and, unlike LPS, fails to induce TNFa 
expression.  Together, DMXAA and other drugs that target IRF-3 may prove to be an 
effective therapeutic in treatment of viral infection of the CNS.  
In addition to the necessity of IRF-3 in the CNS, these in vivo experiments 
illustrate the importance of inspecting several routes of infection.  The initial studies 
examined HSV-1 infection following intravenous inoculation (14).  In such infections, 
the virus would be expected to be shuttled to the liver or spleen, each sites with 
considerable immune cell populations.  The results demonstrated that in such an 
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experiment, IRF-3 had minimal impact whereas IRF-7 deficient mice had significant 
lethality in vivo (14).  However, this method bypasses the tissues associated with 
physiological HSV-1 infections: the epithelia and neuronal cell.  In this study, 
examination of the ocular route of infection permitted evaluation of the full HSV-1 
lifecycle.  While replication was unaffected in the epithelial tissues and the sensory 
ganglia, the brain demonstrated increased susceptibility.  Intravenous infection likely 
provides minimal exposure to brain tissue and thus underestimated the role of IRF-3 in 
limiting HSV-1 infection.  For the same reason, in addition to peripheral infection, 
intracranial injection has been utilized to explore HSV-1 infection of the CNS.  
Numerous factors influence the ability of the virus to enter the CNS following peripheral 
infection; therefore, to adequately evaluate neurovirulence versus neuroinvasiveness, 
direct injection of the virus into the brain is required.   In each case, the differing routes 
of infection answered different in vivo questions.  Intravenous infection examines the 
immune response to a systemic infection.   Ocular challenge examines physiologically 
relevant portions of  HSV-1 infection cycle and intracranial injection evaluates 
neurovirulence and fitness in the brain.  Reliance on a single route or model of infection, 
however, fails to adequately evaluate the immune components being studied. 
 
Future Directions 
An immediate area of interest involves further characterization of HSV-1 
infection in IRF-3-/- brains.  The presented data demonstrates increased viral replication 
due to a deficit in type I IFN production in IRF-3-/- mice.   In combination with 
inflammation, increased viral replication leads to increased lethality in IRF-3-/- mice as 
compared to controls following HSV-1 challenge.  Interestingly, while increased antigen 
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production and distribution was observed in IRF-3-/- brain sections, the staining pattern 
was also distinct compared to WT mice.  As mentioned previously, HSV-1 staining in 
IRF-3-/- brain sections had generalized antigen positive lesions contrasting focal staining 
found in WT brains. One possible explanation suggests that the absence of IRF-3 simply 
results in increased antigen production in the infected brain regions.  An alternative 
explanation suggests a possible shift in tropism with HSV-1 infection of support cells in 
addition to neurons.  While some HSV-1 infection of support cells like astrocytes and 
glial cell have been reported,  neurons are typically the target of HSV-1 infection (20-21, 
34).   Utilizing dual fluorescence staining, changes in viral tropism in IRF-3-/- can be 
determined with specific markers for neurons, astrocytes, microglia, and other cell types 
found within the brain.  Further examination these cell types in vitro may also reveal a 
shift in susceptibility in the absence of IRF-3, similar to BMDC and BMM.   Initial 
examination of cortical neurons demonstrated no change in HSV-1 replication in IRF-3-/- 
cultures as compared to controls (Fig 4.1A); however, primary IRF-3-/-  astrocyte cultures 
demonstrated increased viral replication in initial experiments (4.1B).   
 A second area of interest involves the continued defect of IRF-3-/-  BMDCs  in 
controlling HSV-1 replication following IFN pretreatment.  One possibility is that 
defective autocrine/paracrine IFN amplification or the loss of specific ISGs result in the 
failure to restore complete control of viral replication in IRF-3-/- BMDCs.  An alternate 
hypothesis is that the virus recognition machinery may be required to augment the 
ongoing immune response.  In the absence of type I IFN signaling,  BMDCs fail to 
mature following antigenic stimulations (18).  In these studies, IRF-3-/- BMDCs have 
delayed production in type I IFN and therefore, a likely delay in maturation.  With few 
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exceptions, examination of cytokine profiles revealed a global delay in cytokine 
production from IRF-3-/- BMDCs compared to WT following HSV-1 challenge (Fig 4.2).  
In addition, upregulation of CD86 also lagged behind WT BMDCs following HSV-1 
infection (Fig 4.3).  Interestingly, treatment with IFNβ resulted in CD86 upregulation in 
WT BMDCs but not in IRF-3-/- BMDCs.  This data suggest a possible explanation for the 
continued defect in IRF-3-/- BMDCs following IFN pretreatment.   The lack of IRF-3 
potentially hinders BMDC activation either through reduced IFN amplification, loss of an 
IRF-3 dependent gene product, or absence of a signaling cascade that indicates infection.  
In contrast, treatment with poly IC induced upregulation of CD86 in both WT and IRF-3-
/- BMDC and provides evidence that pattern recognition contributes to BMDC 
maturation.   
 Having determined an impact for IRF-3 dependent pathways on HSV-1 infection 
both in vitro and in vivo, the pathways leading to HSV-1 recognition and subsequent IRF-
3 activation remained to be determined.  Previous reports had identified numerous 
sensors and adaptors involved in the recognition of HSV-1, yet none had been shown to 
have an impact on viral replication.  Using the BMDC cultures,  a variety of immune 
component knockouts were screened for their control of HSV-1 replication; IRF-3-/- 
BMDCs served as a positive control for enhanced viral replication.  The results 
demonstrated that none of the tested immune knockouts recapitulated the in vitro 
phenotype seen in IRF-3-/- BMDCs (Table 4.1).  Known sensors and adaptors from the 
toll-like receptor and RIG-I like receptor pathways had no significant increase in viral 
replication when compared to control cells.  These results suggest that either the pathway 
involved in recognition of HSV-1 has yet to be identified or has yet to be tested.  Another 
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possibility is that multiple sensors and adaptors are involved in HSV-1 recognition and 
compensate for the absence of another pathway.    
 
Concluding Remarks 
 The studies herein demonstrate a role for IRF-3 in the control of HSV-1 infection 
both in vitro and in vivo.  The loss of IRF-3 directly impacts the kinetics and production 
of type I IFN and thus renders IRF-3-/- cells and mice more susceptible to HSV-1 
infection. The study illustrates the importance of IRF-3 mediated recognition pathways in 
the control of viral infection. We hope that these experiments provide a foundation for 
further examination of the early recognition pathways and provide novel insight into the 
interaction between HSV-1 and immune host defenses. 
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Figure 4.1. Preliminary growth curves from primary IRF-3-/- brain cell cultures.  
Primary (A) cortical neurons and (B) astrocytes were infected with HSV-1 at MOI 0.01.  
At indicated times post infection, samples were collected and assayed for viral replication 
via plaque assay on Vero cells.  Results shown are representative of two independent 
experiments. 
 
Figure 4.2. IRF-3-/- BMDCs have a global delay in cytokine production as compared 
to WT BMDCs.  WT and IRF‐3‐/‐ BMDCs were infected at MOI 5 and media harvested 
at 3, 6, 9, and 12 hours post infection. Bead based cytokine assays (Bioplex, BioRad) 
were performed and cytokine titers are expressed as pg/mL. Figures shown represent 
average of three independent experiments. 
 
Figure 4.3.  Maturation was delayed in IRF-3-/- BMDCs as measured by CD 86 
upregulation.  BMDCs were mock treated,  infected with HSV-1 MOI 5, or treated with 
poly IC or 100 units IFNβ  as specified.  Twelve hours post infection, cell were harvested 
and assayed by FACs.   Cells were gated on CD11b positive, PI negative populations and 
assayed for upregulation of CD86, a measurement of BMDC activation. 
 
Table 4.1. Summary of immune deficient BMDCs challenged with HSV‐1 Infection. 
BMDCs were infected at MOIs of 1 and 0.01 and viral titers assayed at 6, 24, and 48 
hours post infection. Each immune deficient BMDC was scored for increase in viral 
replication compared to control cells at either MOI or any time point. 
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Figure 4.1. Preliminary growth curves from primary IRF-3-/- brain cell cultures.  
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Figure 4.2. IRF-3-/- BMDCs have a global delay in cytokine production as compared 
to WT BMDCs. 
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Figure 4.3.  Maturation was delayed in IRF-3-/- BMDCs as measured by CD 86 
upregulation. 
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Table 4.1.  Summary of immune deficient BMDCs challenged with HSV‐1 Infection. 
 
Knockout BMDC HSV-1 Infection 
(relative to WT) 
IRF-3-/- Increased viral replication 
IFNαβγR-/- Increased viral replication 
STAT-1-/- Increased viral replication 
IRF-7-/- Equivalent to WT 
MYD88-/- Equivalent to WT 
MYD88-/-, Trif-/- Equivalent to WT 
IPS-1-/- Equivalent to WT 
TLR-3-/- Equivalent to WT 
TLR-9-/- Equivalent to WT 
TLR-7-/- Not Completed 
RIG-I-/- Equivalent to WT 
MDA-5-/- Equivalent to WT 
MDA-5-/-, TLR-3-/- Equivalent to WT 
DAI-/- Not Completed 
STING-/- Not Completed 
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